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MicroRNAs in Diabetic and TGF-beta-Related Renal Glomerular Injury 
by 
Jennifer Yi-Chun Lai 
 
Chair: Markus Bitzer 
 
Chronic kidney disease (CKD) decreases quality of life, increases mortality, and has 
limited treatment options. Glomerular injury is an early stage of diabetic nephropathy 
(DN), which is a leading cause of CKD, and is characterized by mesangial cell 
proliferation and hypertrophy, loss of podocytes, and increased extracellular matrix 
(ECM) deposition. Critical aspects of these cellular events are mediated by activation 
of the Transforming Growth Factor-beta (TGFβ) signaling cascade. MicroRNAs 
(miRNAs) regulate gene expression in a post-transcriptional level and have been 
implicated as important regulatory elements in the TGFβ signaling cascade. To 
determine the role of miRNAs in DN, we examined miRNA expression in 
micro-dissected glomeruli from kidney biopsies of patients with clinically early DN 




We determined that miR-21 exhibits high expression in renal glomeruli and 
significant correlation with urine albumin-to-creatinine-ratio (ACR) of patients. 
miR-21 is a known regulator of TGFβ signaling and its level is positively associated 
with severity of renal phenotype in TGFβ transgenic mice. We further found that loss 
of miR-21 in TGFβ transgenic mice resulted in accelerated podocyte apoptosis and 
glomerulosclerosis. A similar phenotype was detected in streptozotocin-induced 
diabetic mice. In cultured glomerular cells, loss or inhibition of miR-21 led to 
increased apoptosis of podocytes and increased proliferation of primary mesangial 
cells. Further studies showed that miR-21 represses multiple pro-apoptotic pathways, 
including TGFβ/Smad7, P53, and PDCD4, cell cycle-related genes such as Cdk6 and 
Cdc25a, and ECM-related genes. These results suggest that miR-21 ameliorates 
glomerular injury through repression of multiple injury-mediating signaling pathways.  
 
To further elucidate a miRNA-mediated network mediating DN progression, we 
examined mRNA expression in the same glomerular samples. We identified 
ACR-associated genes that are predicted targets of ACR-associated miRNAs and 
experimentally validated the sequence-dependent repression of candidate target genes 




   
In summary, correlating miRNA expression with specific clinical outcomes identified 
novel mechanisms regulating DN, including a protective role for miR-21 in 
glomerular injury. Furthermore, the approach, which links disease-associated 
miRNAs and mRNAs by target prediction, appears to facilitate identification of 







Chronic kidney disease (CKD) is the pathological change that develops after renal 
injury, such as high blood sugar (hyperglycemia), oxidative stress, or 
immune-mediated damage. CKD can lead to end-stage renal disease (ESRD) 
requiring dialysis support or kidney transplantation. It also results in high morbidity 
and mortality, partially due to an increased cardiovascular event rate, and thereby 
imposes a heavy burden on medical economics1. The increasing prevalence of CKD 
during the past 20 years highlights the public health importance of this disease2. 
According to the 2011 United States Renal Data System (USRDS), Taiwan, Japan, 
and United States are the three countries having the highest prevalence rate of ESRD 
worldwide3. In the United States, the incidence rate of ESRD in 2011 was about 1.3% 
among the Medicare population, but accounted for 8.1% of Medicare costs. Despite 
the high prevalence of ESRD and excessive costs, interventions to prevent or delay 
complications and progression of CKD remain limited. Furthermore, development of 
new treatment options is hampered by our limited understanding of the molecular 
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events associated with the progression from renal injury to ESRD. Facing such a 
medical difficulty, we felt there was an urgent need to advance the knowledge. 
 
Among various renal injuries, diabetic nephropathy (DN), which is caused by 
diabetic mellitus (DM), is the leading cause of ESRD in the United States3. 
Therefore, it is essential to investigate the molecular mechanisms of DN in order to 
ameliorate the development of ESRD. 
 
Kidney structure 
The nephron is the functional unit of the kidney (Figure 1.1). It has two major 
compartments to maintain homeostasis. One is the renal glomerulus, a convolution 
of capillary loops that harbors mesangial, endothelial, and visceral glomerular 
epithelial cells (podocytes). Podocytes stand with extended pedicles on the urinary 
side of the glomerular basement membrane (GBM) of the capillary loops. The foot 
processes of podocytes are interdigiated and connected via a slit diaphragm. The 
endothelium, GBM, and the slit diaphragm and body of podocytes form the 
glomerular filtration barrier to generate primary urine. Mesangial cells are 
specialized smooth muscle cells that are located between the capillary loops, are not 
separated from endothelial cells by the GBM, and are thought to regulate renal blood 
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flow and pressure through glomerular capillaries. The other compartment is the 
tubulo-interstitium, which is composed of tubules that are lined by tubular epithelial 
cells which regulate urine composition through reabsorbing and excreting specific 
molecules from the primary urine. Injuries to the glomeruli (glomerulopathy) or 
tubule-interstitium can initiate a fibrotic response that leads to renal scaring and 
CKD. It has been proposed that glomerulopathy is an early event of DN, and 
initiates the damage in the tubulo-interstitial compartments of the kidney4,5.   
 
Diabetic Nephropathy 
DN results from longstanding DM and is associated with the activation of the 
transforming growth factor-beta (TGFβ) signaling6. The earliest pathological finding 
of DN is glomerulopathy7, characterized by mesangial expansion, podocyte 
depletion, nodular glomerulosclerosis. It clinically manifests as proteinuria followed 
by decreased glomerular filtration function8. The molecular events in glomeruli 
induced by hyperglycemia include increased TGFβ production in the glomerular 
cells leading to mesangial cell proliferation and hypertrophy, podocyte detachment 
from the basement and death, and increased extracellular matrix (ECM) deposition9. 
It has been proposed that podocyte depletion is the initiating event resulting in other 
pathological changes in glomerulopathy10,11. 
4 
 
Transforming growth factor beta (TGFβ) 
The TGFβ superfamily of ligands include Bone Morphogenetic Proteins (BMPs), 
Growth and Differentiation Factors (GDFs), Anti-müllerian Hormone (AMH), 
Activin, Nodal and TGFβs. Members of the TGFβ family are cytokines that bind to 
TGF beta type II receptor, a serine/threonine receptor kinase, which catalyzes the 
phosphorylation of the Type I receptor. Each class of ligands binds to specific type II 
receptors. In mammals, there are seven known type I receptors and five type II 
receptors. TGFβs promote cell proliferation, differentiation, regeneration, and 
apoptosis, but the effects of TGFβ are dependent on the context and organ 
system12,13. In general TGFβs maintain tissue homeostasis and regulate immunity, 
cancer, and fibrotic diseases14.  
Intracellular signaling is initiated by the binding of TGFβ to a type II receptor dimer, 
which recruits a type I receptor dimer to form a hetero-tetrameric complex with the 
ligand. This complex then phosphorylates intracellular signaling molecules. The 
receptor-phosphorylated Smad proteins (Smad2 and Smad3) are central downstream 
effectors to convey and carry out many important context-dependent TGFβ actions 
in the kidney, which are determined by the binding cofactors and the epigenetic 
status of the target gene13 (Figure 1.2). Other than the canonical TGFβ-Smad 
signaling pathway, TGFβ receptor I and II can each individually phosphorylate and 
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activate other downstream kinases that regulate diverse biological functions13.  
 
The TGFβ-Smad signaling pathway has been found to be highly activated in DN. 
Among receptor-phosphorylated Smad proteins, Smad3 mediates important aspects 
in DN progression including podocyte loss due to apoptosis, mesangial cell 
proliferation/activation, and ECM deposition in glomerulus (Figure 1.3)15,16. In 
contrast, Smad2 has an opposing role to Smad3 in renal fibrosis17. In patients with 
DN, decreased podocyte number has been attributed to podocyte loss mediated by 
TGFβ/Smad3-induced apoptosis18. In addition to podocyte loss, mesangial cell 
proliferation and activation promoting ECM deposition is also an important factor in 
the development of glomerulopathy (Figure 1.3)16,19-21.  
 
Albumin-TGFβ1 transgenic mice are characterized by overexpression of active 
TGFβ1 in hepatocytes and high plasma levels of active TGFβ1. Progressive 
glomerulosclerosis is the leading phenotype in TGFβ1 transgenic mice and there are 
mild changes in other organ systems. Therefore, these mice are an established model 
to study the function and signaling of TGFβ in kidney injury22,23. The finding of 
podocyte apoptosis as an early event in TGFβ1 transgenic mice supports the 
hypothesis that TGFβ-induced podocyte apoptosis leads to glomerulopathy11. 
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However, despite the deleterious effects of increased TGFβ activity, TGFβ regulates 
essential homeostatic processes and inhibition of TGFβ ligands or inhibition of the 
ligand binding to its receptors causes pathologic changes24,25. Moreover, although 
Smad3 knockout (KO) mice, have attenuated fibrosis after renal injury26,27, they 
develop mucosal abscesses and have a strongly reduced lifespan28. Therefore, it is 
critical to identify specific downstream signaling mediators in the TGFβ signaling 
cascade that can serve as potential therapeutic targets. 
 
MicroRNAs (miRNAs) 
MiRNAs are small non-coding RNAs that regulate gene expression at 
post-transcriptional level29. They were discovered in 1993 from C. elegans studies30 
and were found to be broadly conserved among different species31. MiRNAs are 
transcribed by RNA polymerase II to form approximately 70 nucleotide long 
pri-miRNAs with a hair-pin loop and stem structure32,33 (Figure 1.4). Pri-miRNAs 
are cleaved by Drosha complex to form pre-miRNA33 and then exported to 
cytoplasm to be further processed by Dicer to form 22 to 24 nucleotides 
double-strand miRNAs (ds-miRNAs)34. Integrating with RNA-induced silencing 
complex (RISC), the ds-miRNAs become mature single-strand miRNAs (ss-RNAs) 
and bind to complementary sequences in 3’ untranslated region (3’UTR) of the 
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target messenger RNAs (mRNAs) causing translational repression or mRNA 
degradation35,36 (Figure 1.4). 
  
Experimental results support functional redundancy between miRNAs and also 
between miRNAs and genes37. In addition to acting as classical binary off-switch 
regulators of genes, miRNAs may also act as neutral regulators to repress protein 
output without compromising biological function35. Some miRNAs are found to be 
critical in maintaining normal cell physiology and loss of the miRNA can result in 
lethality and/or severe functional defect in miRNA KO mice38. miRNAs are often 
integrated into positive and negative feedback loops in signaling pathways and have 
been implicated as modulators of stress responses in many physiologic and 
pathologic processes39. For instance, the transcription factor, P53, binds to the 
promoter region of miRNA34a (miR-34a) and promotes its gene expression. 
Subsequently, the upregulation of miR-34a promotes P53-mediated apoptosis and 
tumor suppression40. Being part of the feed-forward regulation loop, miR-34a targets 
SIRT1 to upregulate P53 activity and reinforces signaling functionality41. There are 
also miRNAs imposing a negative feedback mechanism on a signaling pathway in 




Relationship between TGFβ and miRNA 
Recently, TGFβ/Smad proteins were found to participate in miRNA biogenesis and 
regulation43,44. Specifically, the TGFβ downstream effectors, Smad2/3 proteins, bind 
to the promoter region of miRNAs to increase miRNAs expression at a 
transcriptional level or bind to the stem region of pre-miRNAs to facilitate Drosha 
cleavage process to increase mature miRNA expression at a post-transcriptional 
level45,46(Figure 1.6). Pre-miRNAs, such as miR-21 and miR-23a, have been found 
to have a consensus binding sequence in the stem region for Smad2/3 proteins and 
are regulated by TGFβ45.  
 
MiRNAs are potential oncogenes and also play an important role in heart disease47,48. 
Since TGFβ mediates DN and regulates biogenesis of miRNAs, miRNAs might be 
potential therapeutic targets in the treatment of DN. A few studies have explored the 
role of miRNAs in DN. To date, several miRNAs have been implicated in the 
development of DN49,50. For example, miR-192 is induced by TGFβ and targets the 
E-box promoter repressor, ZEB1/2, to increase E-box-related collagen production in 
mesangial cells49. miR-200 family members, regulated by E-box promoters, are also 
embedded in the ZEB1/2 regulatory network and might play a role in the 
pathogenesis of DN51 (Figure 1.7). Furthermore, miR-377 expression is increased in 
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a high glucose environment in renal cell culture and in mouse model of DN, 
enhances fibronectin production and promotes ECM deposition52. However, those 
current studies focused on in vitro experiments or animal models. It remains unclear 
whether these findings are relevant for human DN. 
 
Evidence is emerging that miRNAs modulate signaling cascades and thereby 
regulate physiologic processes as well as stress response. This raises tremendous 
interest in supplementing or blocking specific miRNA as a clinical intervention. 
Chemically modified oligonucleotide inhibitors have been shown to successfully 
deliver blockage of miRNA in specific tissue organs53. Inhibitors (antagomirs) of 
miR-122 which blocks Hepatitis C virus replication (HCV), can be successfully 
delivered into chimpanzees decreasing Hepatitis C viral load in serum54,55. miR-122 
antagomir is currently in phase 2 clinical trials to target HCV. 
 
Controversy among different studies of miRNAs 
miR-21 is one of the first miRNAs to be linked to cancer biology56. miR-21 is 
associated with a variety of cancers and has an anti-apoptotic effect57,58, and thereby 
is oncogenic59. In addition, miR-21 has also been associated with heart disease48,60 
and kidney disease61,62. In animal models, inhibition of miR-21 was found to 
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attenuate tubulo-interstitial fibrosis in unilateral ureteral obstruction (UUO)61 and 
unilateral ischemia-reperfusion injury62.  
 
Because miR-21 is an anti-apoptotic factor, miR-21 might play a role in diabetic 
glomerulopathy, which is characterized by podocyte apoptosis. Furthermore, TGFβ 
signaling activity is known to induce podocyte apoptosis and regulates miR-21 
biogenesis. However, previous studies about miR-21 focused on the 
tubulointerstitium of kidney61,62.  
 
As kidney is composed of different cell types and most miRNAs are multifaceted as 
well as cell-type-specific, results across different studies and strategies are often not 
consistent49,50,63. For example, Krupa et al. found that loss of miR-192 associates 
with increased fibrosis in kidney biopsies of human DN and loss of miR-192 
promotes fibrogenesis in renal tubular cells50. However, Kato et al. proposed that 
miR-192 promotes fibrogenesis through enhancing TGFβ-induced collagen1a2 
expression in mesangial cells49. Controversy still exists among different miRNA 
studies related to DN and therapeutic development is actively ongoing. For that 
reason, we were prompted to investigate whether miRNA plays a role specifically in 
diabetic glomerulopathy (DG). 
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MiRNA and mRNA interaction 
MiRNAs repress gene expression by binding to mRNA transcripts thereby 
regulating their expression levels and the relationship between miRNA and mRNA 
expression has been broadly studied64. Several algorithms have been developed to 
predict the targeting between miRNAs and mRNA 3’UTR. One such algorithm is 
TargetScan, which is based on matching seed sequences and affinity and 
conservation across species of miRNA:mRNA binding sites64-66. MiRanda, 
calculates the thermodynamic energy of complimentary binding and dynamic 
alignment between miRNAs and mRNA67,68. However, the false prediction rate of 
those algorithms remains high and the number of experimentally verified targets is 
still low69. For example, human miR-21 has 164 predicted targets in Targetscan64-66, 
but only has 42 validated target genes according to miRecord70, a resource of 
experimentally verified miR-target interaction. The other 122 predicted targets were 
either not the sequence-dependent targets of miR-21 or have not been 
experimentally verified.  
  
As a result, many studies have developed new approaches to explore 
miRNA-mRNA interaction that involves more than sequence binding prediction. For 
example, MAGIA integrates the correlation between miRNA and mRNA expression 
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data from the same subjects with pre-existing prediction algorithms71. Other tools 
apply new regression models72,73 or Bayesian inference74 to facilitate the search for 
target genes. However, it is still questionable whether these approaches improve the 
preciseness of identifying target genes or effectively determine the regulatory role of 
miRNA in disease progression. 
 
Therefore, while studying the role of miRNA in human DG, we proposed a new 
approach to investigate miRNA-mRNA interaction based on the association between 
miRNA or mRNA levels and clinical manifestation of specific diseases. 
 
Objectives and aims  
American Indians of the Gila River Indian Community in Arizona are an ethnic 
group that exhibits high rates of type 2 diabetes mellitus and DN75. Previous studies 
have shown an association between inheritability and DN susceptibility in this 
cohort76. This research project, which aims at investigating whether miRNA plays a 
role specifically in DG, examined glomerular miRNA expression in those American 
Indian patients with early diabetic nephropathy in order to (1) determine the 
association between miRNA and human DG, and (2) identify miRNA that may 
modify disease progression. Using animal models including Albumin-TGFβ1 
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transgenic mice, mice with streptozotocin (STZ)-induced beta cell dysfunction and 
DN, and miRNA KO mice23,38, we further examined the role and the regulatory 
mechanisms of miR-21 in TGFβ-related renal glomerulopathy. At last, we proposed 
a new approach to effectively identify miRNA targets based on their association 
with clinical manifestations of specific diseases.  
 
We address the aims and hypothesis in the following three chapters 
Chapter II: MicroRNA-21 ameliorates transforming growth factor-beta-mediated 
glomerular injury 
In this chapter, we determined the association between miRNAs and diabetic clinical 
manifestations, such as the urine albumin-to-creatinine ratio (ACR) and glomerular 
filtration rate (GFR). We profiled miRNA expression in renal glomeruli from kidney 
biopsies of American Indian diabetic patients by quantitative real-time PCR 
(qrt-PCR). We determined that several kidney-related miRNAs exhibited relatively 
high expression in renal glomeruli compared to other miRNAs and had a significant 
correlation with ACR. Among ACR-associated miRNAs, miR-21 had the highest 
expression in renal glomeruli.  
In Albumin-TGFβ1 transgenic mice levels of expression of miR-21 and TGFβ1 are 
positively associated with severity of kidney damage based on histology scores77. 
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Consistent with the previous studies43,62, our data suggested that the higher level of 
TGFβ increases miR-21 in animals with greater renal damage. Apoptosis is a 
process in which cells are eliminated by a specific program78. Since TGFβ induces 
podocyte apoptosis16 and miR-21 has been proposed as an anti-apoptotic factor in 
cancer and ovarian granulosa cells57,58, we further hypothesize that miR-21 acts as a 
negative regulator to limit TGFβ-induced podocyte apoptosis. 
We obtained ubiquitous miR-21 KO mice, which were generated by Cre-Lox 
recombination to remove the sequence of pri-miR21 from the genome79. In order to 
test the hypothesis that miR-21 protects against TGFβ-related glomerulopathy, we 
introduced progressive glomerulopathy into genetically mir21-deficient mice by 
crossing TGFβ1 transgenic (TG) mice with miR-21 KO mice to generate TG/miR-21 
WT and TG/miR-21 KO offspring mice.  
The renal phenotype of TG/miR-21 WT and TG/miR-21 KO littermates showed that 
loss of miR-21 resulted in increased podocyte apoptosis and loss, and progressive 
glomerulopathy. We further examined apoptosis in cultured mouse podocytes 
expressing miR-21 mimics or anti-miR-21 oligonucleotides (inhibitors). We found 
that depletion of miR-21 increased podocyte apoptosis. 
TGFβ induces apoptosis through Smad7 and phosphorylation of Smad316. In 
addition, P53 and programmed cell death 4 (PDCD4) are tumor suppressor proteins, 
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which induce apoptosis80,81. P53 is indirectly suppressed by miR-2180 and PDCD4 is 
targeted by miR-21 in cancer cells81. Other important proteins involved in 
glomerulosclerosis are members of the metalloproteinase (MMP) family and the 
MMP inhibitor, tissue inhibitor of metalloproteinase (TIMP). TIMP inhibits MMP to 
breakdown ECM, and therefore TIMP promotes fibrosis in glomeruli82,83.  
In order to investigate miR-21 regulatory mechanisms in TGFβ-related 
glomerulopathy, we examined the expression levels of the apoptosis-related genes 
and ECM-related genes in TG/miR-21 WT and KO mice and mouse podocytes. We 
found that the mRNA levels of TGFβ receptor 2 (Tgfbr2), TGFβ induced (Tgfbi), 
Smad7, tissue inhibitor of metalloproteinase 3 (Timp3), collagen4a1 (Col4a1), and 
p53 (Tp53) were increased in glomeruli of TG/miR-21 KO mice, the protein levels 
of Pdcd4 as well as phosphorylation of Smad3 were increased in miR-21 
inhibitors-transfected mouse podocytes. We further determined that Smad7 is a 
sequence-dependent target of miR-21. 
 
Chapter III: Loss of miR-21 promotes mesangial cell proliferation and leads to 
increased mesangial expansion in diabetic mice 
In order to test the protective role of miR-21 in glomerulopathy to a greater extent, 
we examined the role of miR-21 in STZ-induced diabetic mice84. We injected STZ 
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into miR-21 WT and KO mice to induce beta-cell dysfunction and thereby 
hyperglycemia and diabetic glomerulopathy. Our results indicated that loss of 
miR-21 in STZ-induced diabetic mice results in more proteinuria and mesangial 
expansion. 
We further found that loss of miR-21 promotes baseline proliferation and cell cycle 
progression of mouse primary mesangial cells (PMC). Cell cycle represents a series 
of events leading from replication of the genetic material to cell division. It 
consisted of G0/G1, S, G2, and M phases and is facilitated by cyclin and 
cyclin-dependent kinases (CDK) complex, 85. Cyclin-dependent kinase 6 (Cdk6) is a 
member of cyclin-dependent protein kinase family, which facilitates cell cycle 
progression86. Cell division cycle 25A (Cdc25a) is a member of phosphatase family 
that is required for cell cycle progression87. Both of them have been proposed as the 
sequence-dependent target of miR-21 in cancer cells81,88. For that reason, we 
performed qrt-PCR to demonstrate that the expression of Cdk6 and Cdc25a was 
increased in the glomeruli of STZ-treated miR-21 KO mice versus STZ-treated 
miR-21 WT mice. Therefore, we suggest that loss of miR-21 facilitates 





Chapter IV: Linking disease-associated miRNA and disease-associated mRNA 
identifies miRNA-mRNA interaction 
In this chapter, miRNA and mRNA were profiled in the renal glomeruli from kidney 
biopsies of the patients with early DN. The levels of expression of both miRNA and 
mRNA were correlated with ACR of patients with early DN. Linking 
ACR-correlated miRNA and ACR-correlated mRNA by two prediction algorithms 
and data from Photoactivatable Ribonucleoside Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP) RNA sequencing89, we identified potential targets 
of miR-200a. 
We further verified the potential targets of miR-200a experimentally. In human 
embryonic kidney (HEK) cells expressing miR-200a mimics, miR-200a repressed 
the expression of RALGPS2, SUPT6H, and EXOC7. We further confirmed that 
EXOC7 is a sequence-dependent target of miR200a by a luciferase assay. We 
concluded that miRNAs and their downstream regulatory genes are associated with 
diseases. Together with the previous findings about miR-21, we propose that some 
miRNAs increase with disease progression as an attempt to limit disease-associated 
gene upregulation and some miRNAs increase with disease progression to further 
repress gene downregulation in disease process. This new concept might provide an 

















Figure 1.1. Overview of kidney, nephron and glomerulus structure. (Adapted 
from “Kidney health library” by UNC kidney center and “Proteinuria in diabetic 
kidney disease: A mechanistic viewpoint” by J.A. Jefferson et al, 2008, KI, 74, P.25. 


















Figure 1.2. Contextual determinants of TGFβ action. (Adapted from “TGFβ 
signaling in context” by Joan Massagué, 2012, Nature Reviews 13, P.616. Copyright 


















Figure 1.3. Cell-specific response to TGFβ and the mechanism leading to 
glomerulopathy. (Adapted from “TGF-beta signaling in renal disease” by E.P. 
Bottinger, and M. Bitzer, 2002, J Am Soc Nephrol 13, P.2604. Copyright 2002 by 






















Figure 1.4. microRNA biogenesis and mRNA silencing mechanism. (Adapted 
from “Regulation of MicroRNA Biogenesis: A miRiad of mechanisms” by B.N. 
Davis, and A. Hata, 2009, Cell Comm Signal 7, P.18. Copyright 2009 by BioMed 











































Figure 1.5. miRNA function in signaling mediation and modulation. (Adapted 
from “MicroRNAs in stress signaling and human disease” by J.T. Mendell, and E.N. 















Figure 1.6. Regulation of miRNA transcription and maturation by TGFβ/Smad 
Signaling. (Adapted from “Smad-mediated regulation of microRNA biosynthesis” 
by M.T. Blahna, and A. Hata, 2012, FEBS Letters 586, P.1906. Copyright 2012 by 

























Figure 1.7. Regulatory mechanisms of miRNAs in diabetic nephropathy. 
(Adapted from “MicroRNAs and Their Role in Progressive Kidney Diseases” by M. 
Kato, L. Arce, and R. Natarajan, 2009, Clin J Am Soc Nephrol 4 P.1255. Copyright 
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MicroRNA-21 Ameliorates TGF-beta Mediated Glomerular Injury 
 
Abstract 
Glomerulopathy is a hallmark of diabetic nephropathy (DN), the leading cause of 
end-stage renal disease (ESRD) in the US. Glomerulopathy is associated with 
imbalance of signaling cascades regulated by transforming growth factor-beta (TGFβ), 
contributing to loss of podocytes and albuminuria. MicroRNAs (miRNAs) regulate 
cellular functions through modulation of signaling cascades via feed-forward loops.  
To identify miRNAs that regulate initiation and development of human DN, we 
associated miRNA expression with albuminuria in micro-dissected glomeruli of 26 
American Indian patients exhibiting clinically early stages of DN. Twenty out of 377 
miRNAs exhibited significant correlation with urine albumin-to-creatinine ratio (ACR) 
(R>0.6; P<0.0001); of those, miR-21 was highly abundant and also exhibited 
significant correlation with ACR in a second cohort (n=22). miR-21 is regulated by 
TGFβ1, which is increased in glomeruli of patients with DN. miR-21-deficient TGFβ1 
transgenic mice exhibit increased proteinuria and glomerular extracellular matrix 
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(ECM) deposition, and decreased number of podocytes. MiR-21-deficiency was 
accompanied by increased TGFβ/Smad-signaling activity and expression of p53, 
Smad7, Pdcd4 and Timp3. 
We conclude that miR-21 functions as a feed-forward loop ameliorating glomerular 
injury through inhibition of TGFβ-induced podocyte loss and ECM deposition, 





DN is a common and devastating microvascular complication in patients with 
diabetes and the leading cause of renal failure in patients requiring dialysis1. 
Although understanding of the underlying mechanisms has progressed significantly 
and interventions have been implemented, diabetic patients with kidney disease 
continue to have a much higher risk of death than diabetic patients with normal renal 
function2, suggesting the need for new drug targets.  
MiRNAs are ~22 nucleotide RNAs that guide RISC to 3’UTR of target mRNAs and 
thereby repress expression of protein-coding genes. miRNAs can regulate large 
numbers of target genes and are often integrated in positive and negative feedback 
loops and have been implicated as modulators of stress responses in many 
physiologic and pathologic processes3.  
In animal models, several miRNAs have been identified that mediate initiation and 
development of DN by altering the expression of TGFβ signaling components4. 
TGFβ is a key factor in the initiation and progression of DN by promoting 
extracellular matrix deposition and loss of podocytes5. TGFβ also regulates 
expression of miRNAs on a transcriptional and post-transcritpional level6. 
Significantly less is known about the role of miRNAs in human DN, but available 
data support that the current knowledge about miRNAs in murine models of DN is 
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also relevant in patients with DN7. 
Here we report our findings from the analysis of miRNA expression in 
micro-dissected glomeruli of kidney biopsies from patients with DN and its 
associations with proteinuria, a clinically relevant parameter of kidney damage and 
prognostic marker of DN progression. Furthermore, we provide experimental 
evidence that miR-21 protects against TGFβ-mediated renal injury by preventing 
podocyte apoptosis via inhibition of pro-apoptotic members of the TGFβ signaling 
cascade. This finding is contrary to the reported pro-fibrotic role of miR-21 in 
models of tubulo-interstitial kidney injury, but it is in line with its well-established 





General characteristics of study cohorts 
Study subjects were divided into two cohorts for testing and validation. Both cohorts 
included more female subjects. Urine was collected over 24 hours and urine albumin 
to creatinine ratio (ACR) was measured. Participants in our cohorts exhibited a 
broad range of ACR (μg/mg), while the mean glomerular filtration rate (GFR, 
iothalamate clearance) was above 90 ml/min/1.73m2 for both cohorts (Table 2.1). 
There was no statistical difference in age, gender distribution, ACR, or GFR at time 
of biopsy between the cohorts. 
 
MiRNA expression profiles generated by RNA sequencing and quantitative 
reanl time PCR (qrt-PCR) exhibit a high correlation   
The amount of total RNA isolated from micro-dissected glomeruli is limited (usually 
ranging from 20 to 200ng per sample). The Taqman-based miRNA array (Applied 
Biosystems) is suitable for these small amounts of total RNA when using 
pre-amplification. We did not detect significant differences in miRNA expression 
with or without pre-amplification using human kidney biopsy tissues. As different 
miRNA profiling methods have been shown to exhibit variable correlations8,9, we 
compared the Taqman-qrt-PCR-based array method with RNA sequencing using the 
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same RNA pool from whole kidneys of a 3 month- old C57BI/6J mouse. We found 
that miRNA sequence reads from RNA sequencing correlated with miRNA cycle 
time generated from qrt-PCR-based miR array (R=0.7, Figure 2.1). For example, 
miR-21 showed very high expression using both RNA sequencing and qrt-PCR array. 
In view of the low RNA content in renal glomeruli and good correlation of miRNA 
profiling between RNA sequencing and qrt-PCR array, we proceeded to apply 
qrt-PCR-based miRNA array with amplification to profile miRNA in the renal 
glomeruli of our cohorts as described10.  
  
Correlation of miRNA expression with ACR   
To identify miRNA relevant for glomerular injury, we associated miRNA expression 
levels with clinical-relevant phenotypes, such as ACR or GFR in our American 
Indian cohorts. Highly significant correlations with ACR were detected for 20 
miRNAs. Among those, miR-21 has the lowest CT value (highest relative abundance 
in the glomeruli) and a statistically very high correlation with ACR in cohort 1 
(testing cohort) (R=0.8, Table 2.2A). Because validation in the same sample was not 
feasible due to a limited amount of RNA, we further validated these findings in 
cohort 2 (validating cohort). miR-21 maintained the high expression in renal 
glomeruli as well as the significant correlation with ACR (R=0.51, Table 2.2B). 
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However, there was no significant correlation between miRNA and GFR (P-value > 
0.05 for all miRNA). Patients with normo- versus micro-albuminuria did not have 
differences in miR-21 levels, whereas patients with macro-albuminuria exhibited 
significantly increased miR-21 in glomeruli (Figure 2.2). 
 
Increased TGFβ gene expression in human DN   
Glomerular mRNA expression profiles of living donors and the American Indian 
subjects with DN have been recently reported11. In this data set, TGFβ1 mRNA 
expression (TGFB1) was higher in glomeruli of subjects with DN compared with 
living donor (fold change=1.22, FDR<0.0001), consistent with previous findings in 
other cohorts12.  
 
miR-21 and TGFβ levels correlate with kidney damage severity in TGFβ1 
transgenic mice 
As miR-21 has been shown to be regulated by TGFβ1, transgenic overexpression of 
TGFβ1 causes proteinuria and progressive glomerulosclerosis13,14, and miR-21 
levels are highly correlated with proteinuria in humans, we examined miR-21 
expression in TGFβ1 transgenic mice. We found that miR-21 expression in kidneys 
of TGFβ1 transgenic mice increased progressively with the severity of kidney 
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damage based on histological scores as described15 (Figure 2.3A). Furthermore, 
TGFβ1 mRNA levels also positively correlated with the severity of kidney damage 
(Figure 2.3B). Therefore, we chose TGFβ1 transgenic mice to further examine the 
function of miR-21 in glomerular injury. 
 
TGFβ1 transgenic/miR-21 KO mice develop increased proteinuria, extracellular 
matrix deposition, and diffuse glomerulosclerosis 
In order to investigate the function of miR-21 in TGFβ-related glomerular injury, we 
obtained miR-21 KO mice. These mice showed no evidence of structural 
abnormalities in the kidney compared to miR-21 WT mice (Figure 2.4). We crossed 
miR-21 KO with TGFβ1 transgenic mice to generate TGFβ1 transgenic (TG)/miR-21 
WT and TG/miR-21 KO littermates in the C57BI/6J background and examined the 
kidney function and structure of those littermates at 4 weeks of age. Qualitative and 
quantitative analysis of urine samples showed increased proteinuria in TG/miR-21 
WT mice as expected, but nearly 50% of TG/miR-21 KO mice developed strongly 
increased albuminuria compared to TG/miR-21 WT mice (Figure 2.5). Plasma 
TGFβ1 concentration (Figure 2.6A) and glomerular TGFβ1 mRNA levels ( Figure 
2.6B) were not different between of TG/miR-21 WT and KO mice. 
Histologically, glomeruli of TG/miR-21 KO mice exhibited increased deposition of 
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Periodic Acid-Schiff (PAS)-positive material (Figure 2.7A) as well as picrosirius red 
staining intensity (Figure 2.7A&B). Consistent with these results, in glomeruli, 
collagen III protein (Figure 2.7A), and collagen III, IV and VI mRNA expression 
were increased (Figure 2.7C). The pattern of ECM deposition in glomeruli of 
TG/miR-21 KO was nodular (Figure 2.7A). No differences were detected in the 
tubulointerstitium between TG/miR-21 WT and TG/miR-21 KO mice. The findings 
are consistent with accelerated glomerulosclerosis induced by TGFβ in the absence 
of miR-21. 
 
Loss of miR-21 is associated with decreased podocyte density in TGFβ1 
transgenic mice   
Loss of podocytes causes glomerulosclerosis16 and has been detected in TGFβ1 
transgenic mice17. To examine whether accelerated glomerulosclerosis in 
TG/miR-21 KO mice is associated with decreased podocyte density, we determined 
podocyte number per glomerular tuft in TG/miR-21 WT and KO mice.  
We applied podocyte-specific nuclear protein, WT1, to identify podocytes in 
glomeruli. Using DAPI nucleic acid and WT1 immunofluorescent staining, we 
found that TG/miR-21 KO mice have a similar number of total cells and 
WT1-positive cells per glomerular tuft compared to their TG/miR-21 WT littermates 
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at 2 weeks of age (Figure 2.8A). At 4 weeks of age, we detected a decreased number 
of total cells and WT1-positive nuclei per glomerular tuft in TG/miR-21-KO mice 
compared to the WT littermates (Figure 2.8B). The data suggested that the decreased 
number of total cells and WT1-positive cells in TG/miR-21 KO mice is due to loss 
of podocytes from 2 weeks old to 4 weeks old. 
 
Loss of miR-21 promotes glomerular cell apoptosis 
miR-21 is an anti-apoptotic factor in cancer and other cells18,19. Podocyte apoptosis 
has been demonstrated to be the initiating event leading to glomerulosclerosis20. 
Therefore, we examined apoptotic events prior to depletion of podocytes in 
glomeruli of 2 weeks old TG/miR-21 WT and KO mice by determining activation 
and cleavage of caspase 321,22. As predicted we detected cleaved caspase 3 by 
immunohistochemistry in both TG/miR-21 WT and KO mice. Furthermore, 
significantly more positive cells were seen in glomeruli of TG/miR-21 KO mice 
(Figure 2.9A). 
To determine specifically whether miR-21 regulates podocyte death, we examined 
podocyte apoptosis in cultured murine podocytes after transfection with antisense 
miR-21 or scramble oligonucleotides. Apoptosis was identified by annexin V-FITC 
and propidium iodide (PI) double-labeling using flow cytometry after serum 
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withdrawal. We found that podocytes transfected with antisense miR-21 
oligonucleotides have significantly more apoptotic cells than podocytes transfected 
with scramble oligonucleotides (Figure 2.9B). Furthermore, when apoptosis was 
assessed by measuring loss of mitochondrial membrane potential, at 24 hours after 
TGFβ1 treatment, podocytes transfected with miR-21 mimic or antisense 
oligonucleotides exhibited decreased and increased apoptosis, respectively, 
compared to cells transfected with scramble oligonucleotides (Figure 2.9C). These 
findings suggested that increased podocyte apoptosis underlies the accelerated 
glomerulosclerosis in TGFβ1 transgenic mice deficient for miR-21. 
 
Loss of miR-21 leads to increased expression of pro-apoptotic proteins 
TGFβ is known to induce apoptosis through Smad7 and phosphorylation of Smad323. 
P53 (Trp53) and programmed cell death 4 (Pdcd4) are tumor suppressor proteins, 
which induce apoptosis24,25. Trp53 was indirectly suppressed by miR-2124 and Pdcd4 
was targeted by miR-21 in cancer cells25. Cross referencing proteins in pro-apoptotic 
pathways with miR-21 predicted targets using TargetScan prediction algorithm 6.126, 
we found that TGFβ receptor 2 (Tgfbr2), TGFβ induced (Tgfbi), Smad7, which are 
members of the TGFβ-signaling cascade and mediators of TGFβ-induced apoptosis26, 
and Pdcd4 are predicted targets of miR-21 (Figure 2.10A).  
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To determine whether miR-21 regulates TGFβ-signaling activity in podocytes, we 
first examined Smad signaling activity in murine podocytes exposed to TGFβ and 
transfected with antisense miR-21 oligonucleotides. Smad3 phosphorylation was 
increased 4 and 24 hours after exposure to TGFβ1 and the phosphorylation of Smad3 
was even higher when miR-21 was suppressed (Figure 2.10B). Levels of Pdcd4 was 
downregulated by TGFβ1 (Figure 2.10C). However, levels of Pdcd4 were increased 
in cells when miR-21 was suppressed. In vivo, Tgfbr2, Tgfbi, Smad7, and Trp53 
mRNAs expression were increased in glomeruli of TG/miR-21 KO mice compared 
to TG/miR-21 WT mice (Figure 2.10D). miR-21 has been reported to target the 
3’UTRs of Pdcd425 and Tgfbr227. 
In podocytes, Smad7 is shown to be induced by TGFβ and induces apoptosis28. 
While inhibition of miR-21 had no effect on Smad7 levels in unchallenged 
podocytes, inhibition of miR-21 led to increased mRNA levels of Smad7 after 24 
hours exposure to TGFβ1 (Figure 2.10E). In a luciferase assay, we co-transfected 
Smad7 3’UTR luciferase construct and miR-21 mimic or antisense miR-21 
oligonucleotides into 293T human embryonic kidney cells. We found the luciferase 
activity of Smad7 3’UTR decreased by miR-21 overexpression and increased by 
miR-21 inhibition in cells (Figure 2.10F). We confirmed that Smad7 is a direct target 
of miR-21 as previously reported29. These results suggest that the anti-apoptotic 
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capacity of miR-21 is at least in part mediated by inhibition of multiple 
pro-apoptotic signals, including Smad7, Trp53, Pdcd4, and TGFβ/Smad3 signaling 
via Tgfbr2. 
 
miR-21 regulates glomerular ECM deposition   
Increased ECM deposition is another hallmark of TGFβ-related glomerulopathy and 
contributes to development and progression of glomerulosclerosis. ECM deposition 
is enhanced by increased collagen production or decreased breakdown of 
extracellular collagen by metalloproteinases (MMPs). Tissue inhibitors of 
metalloproteinase (TIMP) diminish the degradative capacity of extracellular MMPs. 
We found collagen4a1 (Col4a1) as well as Timp3 mRNA was increased in glomeruli 
of TG/miR-21 KO mice versus TG/miR-21 WT mice (Figure 2.7C & 2.10D). Both 
mRNAs are predicted targets of miR-21 (Figure 2.10A). To demonstrate the 
specificity of the increased mRNA levels of the listed miR-21 predicted targets in 
our mice, we showed that Ras homolog gene family member B (RhoB), another 
predicted target genes of miR-21, which have also been implicated in TGFβ 
signaling30, remained unchanged in TG/miR-21 KO mice versus TG/miR-21 WT 
mice (Figure 2.10D). Furthermore, we also found that Timp3 mRNA levels were 
increased in cultured mouse podocytes transfected with antisense miR-21 
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oligonucleotides (Figure 2.10E), and Timp3 mRNA has been experimentally 





In this study, we determined the expression of glomerular miR-21 and miR-221 
exhibiting significant correlation with ACR in a total of 48 patients with early to 
intermediate histopathologic alterations of DN secondary to type 2 diabetes 
mellitus11. Few studies have explored miRNA expression in patients with DN. Krupa 
et al. have identified miRNAs that differentially expressed in kidney tissues of 22 
patients with progressive and non-progressive DN as well as with different disease 
stages7. Because of the different designs from our study including pooled 
formalin-fixed material from whole kidney biopsies, which constitutes mainly 
tubulo-interstitium, significant lower eGFR, and using miR-16 as the reference 
miRNA for normalization, the results from Krupa et al. and ours are not comparable. 
Another study has shown that urinary miR-21 levels were higher in adolescent Hong 
Kong Chinese with albuminuria than that without albuminuria32. We also detected 
increased miR-21 levels in adolescent patients with FSGS compared to controls or 
minimal change disease (personal communication Robert P. Woroniecki and Markus 
Bitzer, unpublished results; ASN 2008, abstract [TH-P0349]). miR-21 is important 
also because it has been identified as a widely expressed and consistently elevated 
miRNA in human cancer and it is a candidate target for intervention because 
inhibition of miR-21 limits tumor growth33. In animal models of kidney injury, 
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miR-21 expression is consistently increased. However, its function remains 
controversial as it has been shown to promote or protect from tubulo-interstitial34,35 
as well as glomerular36,37 damage in different model systems.  
miR-21 is of special interest because in murine models of tubulo-interstitial kidney35 
and lung disease38, miR-21 promotes fibrosis through multiple mechanisms 
including regulation of TGFβ signaling. But the function of miR-21 is complex. In 
the heart, miR-21 has been reported to contribute to myocardial disease39, 
ameliorates development of heart failure after cardiac ischemia40, but is not essential 
for cardiac remodeling41. We have recently shown that inhibition of miR-21 in a 
murine model of myelodysplastic syndrome leads to stimulation of hematopoiesis 
and improvement of phenotype29. Furthermore, miR-21 exhibits oncogenic activity 
through inhibition of apoptosis in most solid cancers and is explored as a therapeutic 
target33. Podocytopenia is an important cause of glomerulosclerosis16 and is a robust 
predictor of disease progression in DN5. Podocyte apoptosis has been detected in 
various animal models of glomerular injury including DN42 and TGFβ1 transgenic 
mice17, and can be induced by TGFβ in cultured podocytes17. Our finding that loss 
of miR-21 results in increased podocyte loss is consistent with anti-apoptotic 
function of miR-21 in cancer, thereby promoting cancer progression24. Albuminuria 
is strongly associated with podocyte damage and miR-21 is strongly correlated with 
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ACR. Therefore, promoting podocyte survival is an important and possibly the most 
prominent function of miR-21 in glomerular injury.  
We determined that miR-21 represses multiple signals that have been shown to 
promote apoptosis in podocytes, including TGFβ/Smad3 signaling17, Smad728 and 
Trp5343. Furthermore, Pdcd4 has been shown to be a pro-apoptotic molecule 
involved in TGFβ1-induced apoptosis in human hepatocellular carcinoma cells. 
Increased Smad3 phosphorylation is likely mediated by de-repression of Tgfbr2, a 
previously reported target of miR-2127. While miR-21 binds the 3’UTR thereby 
repressing expression of Smad738 and Pdcd424, miR-21 inhibits Trp53 expression 
indirectly via targeting Trp53-binding proteins24. Tgfbi induces apoptosis in cancer 
cells44 and it is a predicted target of miR-21, however, it has not been studied in 
podocytes. The increased detection of pro-apoptotic signals in TGmiR-21 KO mice 
is not mediated through TGFβ1 per se, because plasma and intra-renal TGFβ1 levels 
were not different between genotypes (Figure 2.6). Thus, miR-21 mediates its 
function through a large set of target genes.  
The diverse function of miR-21 depends on organ systems and injuries and it is also 
likely to be secondary to the differential expression of target genes. TGFβ activates 
multiple signaling cascades, exhibits cell-type and context-specific functions, and is 
integrated in a complex regulatory network with feed-forward and feedback loops23. 
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Furthermore, maintaining a tight homeostasis of TGFβ-signaling is essential for 
proper function of cells and organ system, underscored by the fact that abundant 
TGFβ1 leads to organ fibrosis45 whereas TGFβ1-deficiency leads to excessive 
inflammatory responses46. Similar to miR-21, miR-192 and miR-200a have been 
implicated in feedback regulation of TGF-beta signaling in DN4.  
The high abundance of miR-21 in human glomeruli and mouse kidneys (Figure 2.1 
& Table 2.2) suggests its high biological activity, because miRNAs are in 
stoichiometric competition with other miRNAs on RISC-loading and they target 
equivalent amounts of mRNA47. Therefore, it is somewhat surprising that 
miR-21-deficient mice do not exhibit developmental or anatomic abnormalities and 
are fertile48 (Figure 2.4). This is consistent with the concept that few target genes are 
repressed by miR-21 under normal cellular conditions but the repression is enhanced 
under cellular stress49.  
In addition to its anti-apoptotic effect, miR-21 regulates ECM deposition. Collagen 
4a1 is a direct target of miR-2150 and was increased in glomeruli of TG.miR-21 KO 
mice. TIMPs inhibit the capacity of MMPs to degrade extracellular collagens and 
thus promote ECM accumulation. We had shown inverse correlation of Timp3 and 
miR-21 expression in human tissues51 and others confirmed repression of Timp3 
expression by miR-21 via direct targeting of the Timp3 3’UTR31. In our study, we 
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showed increased ECM deposition and Timp3 expression in glomeruli of 
TG/miR-21 KO mice. These findings suggest that inhibition of ECM deposition by 
miR-21 contributes to protection against glomerulopathy.  
In summary, our findings support a feed-forward loop in the TGFβ/Smad signaling 
cascade, in which miR-21 represses multiple TGFβ target genes thereby preventing 
TGFβ-induced podocyte apoptosis and ECM deposition in glomeruli (Figure 2.11). 
Our findings further support a context-dependent function and interaction between 




Methods and Materials 
Study subjects. Kidney biopsy samples were collected from 111 Southwestern 
American Indians enrolled in a randomized, placebo-controlled, clinical trial to test 
the renoprotective efficacy of losartan in early type 2 diabetic kidney disease 
(ClinicalTrials.gov No. NCT00340678) as described52. In brief, subjects were 
treated with either losartan or placebo for a median of 5.9 years and a percutaneous 
kidney biopsy was obtained at the end of the treatment period. Kidney biopsy 
specimens were placed into RNAlater® and stored in -20ºC until glomeruli were 
micro-dissected from biopsy cores as described53. Tissue specimens from 48 
subjects were included in this study. 
Urinary albumin and creatinine as well as iothalamate concentrations for GFR 
determination were measured as described52 and values of the examination closest to 
the kidney biopsy were used in the present analyses. This study was approved by the 
Review Board of the National Institute of Diabetes and Digestive and Kidney 
Diseases. Each participant gave informed consent. 
  
miRNA expression analysis. miRNA profiling was obtained using TaqMan miRNA 
assays (Applied Biosystems) as described54. In brief, small RNA fraction (<200 nt) 
was isolated from micro-dissected glomeruli using RNeasy® and MinElute® 
51 
 
Cleanup kits (Qiagen) and reverse transcribed using TaqMan Megaplex RT primers 
(Applied Biosystems). Human glomerular small RNA was amplified by Megaplex 
PreAmp primers (Applied Biosystems). TaqMan array human and rodent miRNA ‘A’ 
cards (Applied Biosystems) were used to obtain miRNA profiles according to the 
manufacturer’s protocol. miRNA expression values, threshold cycle (CT), were 
normalized by U6 small nuclear RNA (snRNA), and RNU44 and RNU48 small 
nucleolar RNA (snoRNA). Delta cycle time (ΔCT) was calculated by subtracting 
miRNAs’ CT from geometric mean of snRNA’s and snoRNA’s CT. Expression level 
in arbitrary units were calculated from 2 to the power of delta cycle time (2ΔΔCT). 
The same protocol was used to determine miRNA expression in kidneys of C57Bl/6j 
mice for comparison with RNA-sequencing method as described below. 
 
RNA sequencing. Total RNA was isolated from kidneys of 3 months old, male 
C57Bl/6j wildtype mice (Jackson lab) using TRIzol® (Invitrogen) as described55 
and 1 µg of total RNA was used for isolation of the small RNA fraction ranging 
from 18 to 40nt size by denaturing polyacrylamide gel electrophoresis. Library 
preparation and sequencing was performed in the Genomics Core Facility of Albert 
Einstein College of Medicine using Illumina’s Genome Analyzer III. The protocol 
was described as (http://wasp.einstein.yu.edu/index.php/Protocol:RNA_seq). 
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Sequence reads (approximately 8x106 per sample) were aligned to the Genome 
Reference Consortium Mouse and miRNAs were annotated using a published 
automated bioinformatics pipeline56. 
 
Qrt-PCR. For expression analysis of specific transcripts, mRNA and 
miRNA-specific stem-loop primers and TaqMan probe sets (Applied Biosystem) 
were used according to manufacturer’s protocols, on an ABI 7900HT real-time PCR 
system as described54. 
 
Mouse models. miR-21 knockout mice (miR-21-KO) were generated from 
disruption of the miR-21 sequence as described48, and crossed with albumin-TGFβ1 
transgenic mice (TGFb-TG)45. Experiments were conducted in male littermates in 
C57Bl/6j background. These procedures were in accordance with the policies of the 
University of Michigan Institutional Animal Care and Use Committee. 
  
Tissue staining. Periodic acid Schiff and picrosirius red staining was performed on 
formalin-fixed paraffin-embedded mouse kidney sections as described28. For 
picrosirius red staining, percent glomerular area exceeding a minimum HSI (hue, 
saturation, intensity) threshold were determined from images of at least 50 glomeruli 
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per sample at 20x magnification using MetaMorph® image analysis software. WT1 
staining was performed as described28.  
 
Glomerular podocyte density. Podocyte density was determined for at least 30 
glomeruli of each sample using nuclear (DAPI-staining) and podocyte 
(WT1-staining) counts normalized to glomerular volume calculated using 
glomerular tuft area measurements and the Weibel equation as described57.  
 
Urine protein and creatinine measurement. Spot urine samples were collected 
non-invasively from mice. Urine creatinine concentrations were determined by 
QuantiChromTM Creatinine Assay Kit (BioAssay Systems). Urine protein was 
qualitatively assessed by Coomassie blue staining of SDS-PAGE gel loaded with 
equal amounts of urine and quantitatively by Bio-Rad protein assay (Bio-Rad).  
 
Isolation of mouse glomeruli. Isolation of glomeruli from TG/miR-21 WT and KO 
mice using beads and sieving method was performed as described achieving >90% 
purity58 .  
 





miRNA transfection. miR-21 oligonucleotide mimic (Ambion) or inhibitor (Exiqon) 
were applied with Lipofectamine® RNAiMAX Reagent (Invitrogen) to transfect 
podocytes at least 10 days after thermoshift. Using fluorescence-labeled scrambled 
oligo’s we detected about 40 to 50% of cells with positive fluorescence signals. 
 
Immunoblot assay. Total and phosphorylated proteins were detected by Western 
blotting using the following primary antibodies: phospho-smad3 (Rockland, 
600-401-919), total smad2/3 (cell signaling, #3102) and GAPDH (Sigma, G8795). 
IRDye® secondary antibodies and Odyssey infrared imaging system (LI-COR 
Biosciences) were used for quantification. 
  
Apoptosis assays. In vivo apoptosis was detected by immunohistochemistry with 
cleaved-caspase-3 antibody (Cell Signaling, Asp175) on FFPE tissue sections and 
manual counting of positive cells. For quantification of apoptosis of cultured cells, 
annexin-V/propidium iodide positive cells (determined by flow cytometry, 
Invitrogen assay kit) and cells negative for mitochondrial membrane potential 





Luciferase reporter assays. The Smad7 3’UTR was amplified by PCR using 
genomic DNA from mouse embryonic fibroblasts; sequence of the sense primer 
AATAACTAGTTCGGTCGTGTGGTGGGGAGAAGA; antisense primer 
GATAAGCTTGCGCAAAGTGCATCTTTTCTTTATTCT. The amplified PCR 
product was cloned into pMIR-REPORT™ miRNA Expression Reporter Vector 
(Ambion/Invitrogen) between SpeI and HindIII sites downstream of the luciferase 
coding sequence. The 3’UTR construct, renilla luciferase plasmid, and miR-21 
mimic or anti-sense oligonucleotides were co-transfected into 293T human kidney 
embryonic cells using lipofectamine LTX and plus reagents (Invitrogen). Luciferase 
activity was measured 48 hours after transfection in luciferase assay plate reader. 
 
Statistical analysis. Participants in the kidney biopsy protocol were placed at 
random into either cohort one (training cohort) or two (validation cohort). General 
characteristics, including age and GFR, were compared between cohorts using t-tests, 
while two-group proportion test was used for gender distribution. Wilcoxon rank 
sum test was used for comparison of the non-normally distributed ACR values 
between Pima cohorts. Correlation analysis and significance was determined by 
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Pearson correlation using an R script. T-tests were used to compare sirius red 





Table 2.1. Characteristics of American Indian testing and validating cohort 
  Testing cohort Validating cohort P-value 
No. of subject 26 22  
Age: Mean (SD) 43(9.1) 46(11.3) 0.3974 
Gender: % of female 81% 82% 0.9292 
ACR: Mean (SD) 498(1492) 194(518) 0.2466 
GFR: Mean (SD) 159(58) 137(38) 0.1436 
ACR: urine albumin-to-creatinine ratio (μg/mg). GFR: glomerular filtration rate (ml/min/1.73m2)  






















Figure 2.1. miRNA expression profiling in the mouse kidney using RNA 
sequencing and qrt-PCR. Expression levels of miRNAs determined by RNA 
sequencing and qrt-PCR were significantly correlated (R=0.7, P < 0.0001, No. of 
miRNAs included: 287; miRNA with 0 counts in RNA sequencing or undetermined 
cycle time (CT) in qrt-PCR were excluded). RNA sequencing read counts were 
transformed to natural logarithmic value. miR-21 (white circle) was highly 






































q-rtPCR cycle time value 
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Table 2.2A. Correlation between miRNA and ACR in testing cohort 
miRNA P value Correlation with ACR Expression level 
hsa-miR-21 <0.00001 0.80 high 
hsa-miR-150 <0.00001 0.74 high 
hsa-miR-192 <0.00001 0.70 high 
hsa-miR-221 <0.00001 0.67 high 
hsa-miR-532-3p <0.00001 0.64 high 
hsa-miR-135a <0.00001 0.81 medium 
hsa-miR-429 <0.00001 0.79 medium 
hsa-miR-660 <0.00001 0.77 medium 
hsa-miR-142-3p <0.00001 0.77 medium 
hsa-miR-200a <0.00001 0.76 medium 
hsa-miR-218 <0.00001 0.74 medium 
hsa-miR-455-5p <0.00001 0.71 medium 
hsa-miR-450a <0.00001 0.66 medium 
hsa-miR-181a <0.00001 0.65 medium 
hsa-miR-642 <0.00001 0.89 low 
hsa-miR-32 <0.00001 0.85 low 
hsa-miR-511 <0.00001 0.77 low 
hsa-miR-187 <0.00001 0.74 low 
hsa-miR-452 <0.00001 0.69 low 





Table 2.2B. Correlation between miRNA and ACR in validating cohort 
miRNA  P value  Correlation with ACR Expression level 
hsa-miR-132  <0.00001 0.64 high 
hsa-miR-454  <0.00001 0.59 high 
hsa-miR-337-5p  <0.00001 0.58 high 
hsa-miR-21  0.01 0.51 high 
hsa-miR-191  0.03 0.47 high 
hsa-miR-221  0.03 0.46 high 
hsa-miR-186  0.03 0.46 high 
hsa-miR-140-5p  0.03 0.46 high 
hsa-miR-125a-5p  0.03 0.46 high 
hsa-miR-212  <0.00001 0.96 medium 
hsa-miR-224  <0.00001 0.94 medium 
hsa-miR-133b  <0.00001 0.58 medium 
hsa-miR-18a  0.02 0.51 medium 
hsa-miR-140-3p  0.03 0.46 medium 
hsa-miR-148b  0.03 0.46 medium 
hsa-miR-133a  0.04 0.43 medium 
hsa-miR-299-5p  <0.00001 0.83 low 













Figure 2.2. Glomerular miR-21 levels in American Indian patients with 
normo-albuminuria, micro-albuminuria and macro-albuminuria. miR-21 levels 
determined by qrt-PCR were similar in patients with normo- (N=19) and 
micro-albuminuria (N=22) (P=0.8). However, miR-21 levels increased significantly 












Figure 2.3. miR-21 and TGFβ1 expression levels in kidneys of TGFβ1 
transgenic mice. Qrt-PCR showed (A) miR-21 levels increased with kidney damage 
severity inferred from histology score. Levels were significantly higher in TG severe 
phenotype (TG/severe) (N=8) and mild phenotype (TG/mild) (N=6) compared to 
wild type (WT) (N=5) (P < 0.001 in #TG/severe versus TG/mild and *TG/mild 
versus WT). (B) TGFβ1 levels also increased with kidney damage severity. Levels 














Figure 2.4. Kidney histology and structure in miR-21 WT and KO C57BI/6J 
mouse at 12 weeks old. (A) Periodic acid Schiff (PAS) staining of 
tubulointerstitium or glomerulus showed normal kidney structure in miR-21 WT and 
KO littermates. (B) Sirius red staining of tubulointerstitium or glomerulus showed 
no staining difference between miR-21 WT and KO littermates. (C) Transmission 
electron microscopy (TEM) showed normal podocyte morphology and slit 
diaphragm in miR-21 WT and KO littermates. (D) Histogram and statistical analysis 
of sirius red staining intensity showed no difference in tubulointerstitium or 
glomerulus between miR-21 WT (N=4) and KO (N=5) littermates (P = 0.8 in 





















Figure 2.5. Examination of proteinuria in TG/miR-21 WT and KO mice. (A) 
Urine protein to creatinine ratio showed that TG/miR-21 KO mice (N=19) had 
increased proteinuria with more variability than TG/miR-21 WT mice (N=12) at 4 
weeks of age. (B) Coomassie blue stain of urine showed that TG/miR-21 KO mice 
(N=6) had more severe proteinuria than TG/miR-21 WT mice (N=7; normalized by 












Figure 2.6. TGFβ1 levels in TG/miR-21 WT and KO mice. (A) Plasma TGFβ1 
levels were not different between TG/miR-21 WT (N=11) and KO (N=17) mice (P = 
0.053). (B) Qrt-PCR showed that glomerular TGFβ1 mRNA levels were not 





























Figure 2.7. Examination of kidney histology in TG/miR-21 WT and KO mice. 
(A) PAS staining showed increased deposition of PAS material and decreased 
cellularity in glomeruli of TG/miR-21 KO compared to TG/miR-21 WT mice, but no 
difference in the tubulointerstitial area. Picrosirius red staining of glomerulus 
showed increased signal intensity and development of nodular pattern in glomeruli 









the tubulointerstitial area. Consistent with increased ECM deposition detected by 
picrosirius red staining, immunohistochemistry staining showed increased collagen 
III deposition in the glomerulus of TG/miR-21 KO. (B) Histogram and statistical 
analysis of picrosirius red staining intensity showed significantly higher staining 
intensity in glomeruli of TG/miR-21 KO (N=7) versus WT mice (N=9) (*P < 0.01). 
In the tubulointerstitium, staining intensity between TG/miR-21 WT and KO mice 
was not significantly difference (P = 0.08). (C) Qrt-PCR showed higher expression 
of collagen1a1, collagen4a1, collagen6a1 mRNA levels in glomeruli of TG/miR-21 












Figure 2.8. Podocyte number in glomeruli of TG/miR-21 WT and KO mice. (A) 
The immunofluorescent staining did not reveal difference in the number of cells 
(DAPI-positive) and podocytes (DAPI- and WT1-positive) per glomerular tuft in 
TG/miR-21 WT (N=3) versus KO mice (N=5) at 2 weeks of age. (B) The number of 
total cells (*P < 0.05) and podocytes (*P < 0.01) per glomerular tuft were 
significantly decreased in TG/miR-21-KO mice (N=4) versus TG/miR-21-WT mice 
(N=5) at 4 weeks of age. DAPI (blue), WT1 (red), podocytes (pink in merge). The 
number of cells per glomerular tuft was normalized by the number of DAPI-positive 























Figure 2.9. Apoptotic events in glomeruli of TG/miR-21 WT and KO mice and 
in miR-21 mimic or antisense oligonucleotide-transfected immortalized mouse 
podocytes. (A) Cleaved caspase-3 staining showed a higher number of positively 
stained cells per 100 glomerular section of TG/miR-21 KO mice (N=7) compared to 
the WT mice (N=3) at 2 weeks old. (B) Annexin V-FITC and propidium iodide (PI) 
double labeling in flow cytometry showed that mouse podocytes transfected with 
antisense miR-21 oligonucleotide (miR-21 inhibitor) exhibited increased number of 
apoptotic cells than the scramble transfection (21% v.s. 6.9%) (C) Staining of 
mitochondrial membrane potential in mouse podocytes transfected with miR-21 
mimic or inhibitor and treated with TGFß1 (10 ng/ml) for 24 hours indicated that 
inhibition of miR-21 results in loss of mitochondrial membrane potential consistent 
with increased apoptosis, whereas overexpression of miR-21 results in decreased 
apoptosis compared to the scramble transfection. In vitro experiments were 













































Figure 2.10. Examination of candidate miR-21 target gene expression in mouse 
podocytes and glomeruli of TG/miR-21 WT and KO mice. (A) Predicted target 
sites of miR-21 in 3’UTRs of Tgfbr2, Tgfbi, Smad7, Pdcd4, Timp3, and Col4a1 
(www.targetscan.org). (B) Protein measurement showed increased level of 
phospho-Smad3 in miR-21 inhibitor transfected podocytes compared to the 
scramble transfection at 4 and 24 hours after TGFß1 (10ng/ml) treatment (*P < 0.05; 
N=3,). (C) PDCD4 protein level was decreased in podocytes at 24 hours after 
TGFß1 treatment compared to no treatment (*P < 0.05; N=4). PDCD4 was increased 
in miR-21 inhibitor transfected podocytes compared to scramble transfection with or 




























Figure 2.10. Examination of candidate miR-21 target gene expression in mouse 
podocytes and glomeruli of TG/miR-21 WT and KO mice. (D) TG/miR-21-KO 
mice (N=3) exhibit higher glomerular mRNA expression of Tgfbr2, Tgfbi, Smad7, 
Tp53, and Timp3 compared to TG/miR-21-WT mice (N=4) assayed by qrt-PCR (*P 
< 0.05). The level of RhoB, also a predicted target of miR-21, did not differ between 
TG/miR-21-WT and KO mice (P = 0.9). (E) At 24 hours of TGFß1 treatment, Smad7 
and Timp3 were increased in miR-21 inhibitor-transfected podocytes. Timp3 was 
also increased in miR-21 inhibitor-transfected podocytes without TGFß1 treatment 
(*P < 0.05, N=6). (F) Luciferase assay of 293T human embryonic kidney cells 
co-transfected with Smad7 3’UTR luciferase construct and miR-21 mimic or 
inhibitor showed decreased luciferase activity after miR-21 overexpression (*P < 
















Figure 2.11. Proposed function of miR-21 as a feed-forward loop in TGFβ 
signaling in glomerular injury. The role of Pdcd4 (dashed line) in TGFβ-induced 
renal cell survival and death has not been explored yet. Trp53 is indirectly regulated 
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Loss of miR-21 promotes mesangial cell proliferation and leads to increased 
mesangial expansion in diabetic mice 
 
Abstract 
DN is the leading cause of ESRD and imposes heavy burden on the medical economy. 
Mesangial expansion is an early finding in DN, and is associated with mesangial cell 
proliferation as well as hypertrophy. We have previously identified miR-21 to be 
increased in micro-dissected glomeruli of patients with early to intermediate 
pathologic changes of DN. In addition, we had shown that loss of miR-21 is 
associated with acceleration of glomerulopathy in Albumin-TGFß transgenic mcie. To 
test the hypothesis that miR-21 inhibits the development of mesangial expansion and 
DN, we examined glomerular pathology in streptozotocin (STZ)-induced 
hyperglycemic, miR-21 KO mice. 
STZ (50mg/kg) was injected intraperitoneally (IP) into 10 weeks old miR-21 wildtype 
(WT), heterozygous (HET), and knockout (KO) mice in pure DBA background for 5 
days. Proteinuria was assessed every 4 weeks for 20 weeks after STZ treatment. 
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Kidney histology and mRNA expression were examined at 20 weeks after STZ 
treatment. For in vitro studies, primary mesangial cells (PMC) were isolated from 
miR-21 WT and KO mice. Cell proliferation and cell cycle distribution were studied 
in miR-21WT and KO PMCs.  
STZ-treated miR-21 KO mice developed more albuminuria and glomerular 
mesangial expansion compared to the WT or HET littermates. miR-21 KO PMC 
showed faster proliferation and more cells accumulating at the synthesis (S) phase of 
the cell cycle than miR-21 WT PMC. The mRNA expression of cell cycle regulators, 
cyclin-dependent kinase 6 (Cdk6) and cell division cycle 25A (Cdc25a), were 
increased in the renal glomeruli of STZ-treated miR-21 KO mice versus STZ-treated 
miR-21 WT mice.  
Our results suggested that miR-21 targets Cdk6 and Cdc25a to protect against 
mesangial expansion in DN. Therefore, we propose that miR-21 limits DN by 




DN is the renal injury caused by hyperglycemia. Clinically, it manifests as 
proteinuria and loss of kidney function. Histologically, it is characterized by 
mesangial expansion, glomerulosclerosis and tubulointerstitial fibrosis1. DN is the 
leading cause of ESRD in the United States and increases cardiovascular events as 
well as mortality2. Therefore, several different diabetic murine models have been 
developed to mimic human DN to explore mechanisms for DN and develop new 
therapies3. Nevertheless, to date, none of these diabetic murine models recapitulate 
all the microvascular and macrovascular injury observed in human DN3. 
STZ-induced DN in mice is a well-established diabetic murine model. It is 
characterized by mesangial expansion, nodular sclerosis, and arteriolar hyalinosis3. 
However, different susceptibilities to DN were noted in different inbred mouse 
strains. For instance, C57BL/6 mice are relatively resistant to diabetic kidney injury, 
while DBA mice develop mesangial expansion and mesangial sclerosis, which 
represent early human DN3,4. 
In previous chapters, we determined the role and regulatory mechanisms of miR-21 
in progressive glomerulopathy in TGFβ transgenic mice. We noticed that miR-21 
inhibits apoptosis in podocytes exposed to TGFβ. However, because miR-21 has 
been linked to fibroblast activation in heart disease5 and epithelial mesenchymal 
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transition (EMT) in rat tubular cells6, the latter findings suggest that the interaction 
of miR-21 with TGFβ signaling may be context-dependent and/or cell-specific. 
Therefore, the function of miR-21 in DN needs to be further validated.  
Therefore, we used STZ-induced glomerulopathy in DBA mice to test our 
hypothesis that miR-21 has a protective role in mesangial expansion and DN. We 
also determined the function of miR-21 in primary mesangial cells from miR-21 WT 





STZ-treated miR-21 WT and KO DBA mice developed hyperglycemia 
In order to investigate the function of miR-21 in DN, we injected STZ into miR-21 
WT, HET and KO DBA mice to selectively induce pancreatice beta-cell dysfunction 
and associated hyperglycemia. All miR-21 WT, HET and KO mice developed 
hyperglycemia with blood glucose levels up to 400 mg/dl at 2 weeks and 600 mg/dl 
at 20 weeks after STZ treatment (Figure 3.1). No difference in blood glucose levels 
was detected between genotypes.  
  
STZ-treated miR-21 KO mice developed more proteinuria 
Before treatment with STZ, miR-21 KO mice showed no evidence of structural 
abnormalities in the kidney compared to miR-21-WT mice (Figure 2.4). Since 
proteinuria is an indicator of glomerular damage, we measured urine 
albumin-to-creatinine ratio (ACR) in STZ-treated miR-21 WT and KO mice. After 4 
weeks of STZ treatment, miR-21 WT, HET and KO mice developed albuminuria 
(Figure 3.2). At 8, 12, 16, and 20 weeks after STZ treatment, miR-21 KO and HET 
mice had significantly higher ACR than the STZ-treated WT littermates, with 




STZ-treated miR-21 KO mice had increased mesangial expansion and 
extracellular matrix deposition 
To determine the extent of glomerular damage of STZ-treated miR-21 WT, HET and 
KO mice, we quantified the area of mesangial expansion by Periodic acid-Schiff 
(PAS) staining at 20 weeks after STZ treatment. STZ-treated miR-21 KO mice 
showed increased PAS-positive material deposited in glomeruli compared to 
STZ-treated miR-21 WT mice (Figure 3.3A). Using quantitative image analysis, the 
calculated mesangial index (%) was significantly higher in STZ-treated miR-21 KO 
mice than in STZ-treated WT and HET littermates (Figure 3.3B).  
 
Loss of miR-21 promotes PMC proliferation 
To examine the function of miR-21 specifically in mesangial cells, we isolated PMC 
from miR-21 WT and KO mice. In scratch-wound assay, PMC from miR-21 KO 
mice showed more rapid wound closure than WT PMCs. This could be due to either 
increased migration speed or proliferation rate (Figure 3.4). In a colorimetric assay 
of cell proliferation (MTT assay), we found that PMC from miR-21 KO mice had a 
higher number of cells than PMC from miR-21 WT mice after 24 hours (Figure 3.5). 
Based on these findings as well as the findings from other previous studies that 
miR-21 regulates cell cycle7,8, we studied the cell cycle distribution of PMC from 
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miR-21 WT and KO mice at 20 hours after 10% fetal bovine serum stimulation. The 
cell cycle study indicated that PMC from miR-21 KO mice had a higher percentage 
of cells accumulating in synthesis phase (S phase) compared to PMC from miR-21 
WT mice (Figure 3.6). These results suggest that miR-21 contributes to growth 
arrest in PMC and loss of miR-21 promotes mesangial cell proliferation. 
 
Loss of miR-21 increases the expression of Cdk6 and Cdc25a 
Cdk6 is a member of cyclin-dependent protein kinase family, which facilitates cell 
cycle progression9. Cdc25a is a member of phosphatase family that is required for 
cell cycle progression10. Both of them have been proposed as the 
sequence-dependent target of miR-21 in cancer cells8,11. For that reason, we have 
performed qrt-PCR to examine the expression of Cdk6 and Cdc25a in STZ-treated 
miR-21 WT and KO mice. Our result showed that the mRNA expression of Cdk6 
and Cdc25a was increased in the glomeruli of STZ-treated miR-21 KO mice 
compared to STZ-treated miR-21 WT mice (Figure 3.7). Therefore, we proposed 
that loss of miR-21 aggravates the glomerular injury in diabetic mice by 




In this chapter, we investigated whether miR-21 has a protective role in DN by 
examining kidney function and histology in diabetic miR-21 null mice. We used 
STZ-induced hyperglycemic mice a model for type I diabetes, to examine the role of 
miR-21 in DN. Our results revealed that loss of miR-21 induces more severe 
proteinuria and mesangial expansion in diabetic mice. This evidence supports the 
previous finding that loss of miR-21 exasperates glomerular damage. Additionally, 
we noticed that loss of miR-21 promotes mesangial cell proliferation by regulating 
cell cycle progression. 
STZ-induced diabetes is an established mouse model for examining the pathogenesis 
of human DN, especially in the DBA/2J mouse strain4. In STZ-treated DBA/2J mice, 
hyperglycemia starts to manifest within 2 weeks of STZ treatment and serum 
glucose levels rise to 500 to 600 mg/dl after 20 weeks STZ treatment4,12. ACR in 
non-treated DBA/2J mice is around 20 to 30 μg/mg and albuminuria develops within 
5 weeks of STZ treatment4. Consistent with previously published findings3,4,12, the 
STZ-treated miR-21 WT and KO mice had typical hyperglycemia manifestation 
(Figure 3.1) and ACR levels gradually increased after 4 weeks of STZ treatment. 
Treated miR-21 WT mice had typical albuminuria level (400 to 500 mg/dl) 
compared to the treated DBA/2J mice in other people’s experience4 and the treated 
miR-21 KO mice had almost 3 to 4 times more albuminuria compared to their 
87 
 
control WT littermates.  
In terms of kidney histopathological change, at as early as 5 weeks after STZ 
treatment, glomerular hypertrophy is the typical feature in STZ-treated DBA mice12. 
When disease progresses, mesangial expansion becomes the major pathological 
feature similar to what we have found in treated-miR-21 WT and KO mice at 20 
weeks after STZ treatment. Furthermore, mesangial sclerosis developed in treated 
miR-21 KO mice (Figure 3.3). Other features of DN including arteriolar hyalinosis 
or nodular glomerulosclerosis seldom develop in STZ-treated DBA/2J mice12 and 
there is no current diabetic murine model that recapitulates all of the clinical features 
of human DN3. In addition, despite being more susceptible to DN, STZ-treated 
DBA/2J mice only develop mesangial expansion and sclerosis, which represent the 
early stage of DG. Therefore, STZ-treated miR-21 KO mouse is a suitable model to 
test the protective role of miR-21 in glomerulopathy. 
miR-21 is of special interest because in murine models of renal interstitial fibrosis13 
and lung disease14, miR-21 promotes fibrosis through multiple mechanisms 
including regulation of TGFβ signaling. On the other hand, in both TGFβ1 
transgenic and diabetic mice, miR-21 protects against glomerulopathy. This diverse 
function of miR-21 may depend on different organ systems and injuries. It is also 
likely to be secondary to the differential expression of target genes in different cells. 
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For example, tumor suppressor PTEN was shown to be target gene of miR-21 in 
mesangial cells15 and cancer cells16. However, in our culture system, while 
overexpressing miR-21 in 293T human embryonic kidney cells, we did not observe 
repression of miR-21 on PTEN (Figure 3.8A). We also did not detect the difference 
in the protein expression of PTEN in miR-21 WT, HET, and KO DBA/2J mice 
(Figure 3.8B).  
The cell cycle, consisting of G0, G1, S, G2, and M phases, represents a series of 
events leading cells from replication to cell division. The check-point of each phase 
transition is tightly regulated by cyclin and cyclin-dependent kinases (CDK)17,18. 
Dysregulation of these proteins can promote cancer formation19 as well as contribute 
to the pathogenesis of DG17. In vitro, TGFβ has been shown to induce CDK 
inhibitors, block cell cycle progression, and result in PMC hypertrophy20-22. In our 
PMC culture system, we noticed that loss of miR-21 promoted PMC proliferation. 
Consistent with our findings, Wang et al. also found that miR-21 targets Cdc25a and 
inhibits G1 to S transition in colon cancer cells8. In addition, miR-21 is reported to 
upregulate CDK inhibitor, P21, by targeting its transcriptional inhibitor, Nf1b 
(Nuclear factor 1 B-type)23. Our results using a cell proliferation assay and assessing 
the cell cycle support that loss of miR-21 upregulates cell cycle-related proteins to 
prompt cell cycle progression.  
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Cdk6 is a member of the cyclin-dependent protein kinase family. This kinase first 
appears in mid-G1 phase, together with Cdk4, is important for cell cycle G1 phase 
progression and G1 to S transition9. Cdc25a is a member of phosphatase family that 
dephosphorylates and activates CDK–cyclin complexes, such as CDK2–cyclin E at 
the G1–S transition and CDK1–cyclin B at the entry into mitosis10. Interestingly, 
Cdk6 and Cdc25a mRNA has been shown to be a sequence-dependent target of 
miR-21 in cancer cells8,11. Our in vivo results also showed that Cdk6 and Cdc25a 
mRNA level were increased in glomeruli of STZ-treated KO mice. This supports the 
hypothesis that loss of miR-21 promotes mesangial cell proliferation from 
upregulating Cdk6 and Cdc25a. 
Despite previous findings that TGFβ or hyperglycemia induces CDK inhibitors to 
cause cell cycle arrest and mesangial cell hypertrophy24,25, a biphasic growth 
response of mesangial cells to TGFβ has been described17. It is possible that before 
the hypertrophic stage, an increase of Cdk6 or Cdc25a caused by loss of miR-21 
facilitates an initial proliferation stage of mesangial cells leading to mesangial 
expansion. In support of this, Zhang et al. have shown that overexpression of 
miR-21 inhibits mesangial cell proliferation in diabetic db/db mice26. 
In summary, the findings in our diabetic mouse model provide additional evidence 
that miR-21 has a protective role in TGFβ-related glomerulopathy including DG. 
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miR-21 targets different regulatory mechanisms in different glomerular cells, which 
reiterates the cell-specific and multi-facet nature of miRNA. Our study suggests an 





Methods and Materials 
Mouse model.  miR-21-KO C57BL/6J mice were generated from disruption of the 
miR-21 sequence as described27. miR-21 WT and KO DBA/2J mice were obtained 
by backcrossing the C57BL/6J mice colony onto the DBA background strain for 6 or 
more generations. STZ, dissolved in sodium citrate buffer, was IP injected into 10 
weeks old miR-21 WT and KO DBA/2J mice in a dose of 50mg/kg as previously 
described28. These procedures were in accordance with the policies of the University 
of Michigan Institutional Animal Care and Use Committee. 
 
Blood glucose measurement. Adequate amount of blood was obtained from tail 
vein of mice. Blood glucose was measured by using Accu-Chek Comfort Curve 
Diabetic Test Strips before STZ treatment and at 2 weeks, 6 weeks, 12 weeks, and 
20 weeks after STZ treatment. 
 
Urine albumin and creatinine measurement. Spot mouse urine was collected 
non-invasively from mice 1-2 days before STZ treatment and at 4 weeks, 8 weeks, 
12 weeks, 16 weeks and 20 weeks after STZ treatment. Urine albumin was 
measured by Albuwell M kit (Exocell Inc) and urine creatinine was measured by the 




Tissue staining and analysis. Mouse kidneys were harvested, fixed in 4% 
paraformaldehyde overnight, and paraffin-embedded. The kidney sections were cut 
in 3μm thickness, deparaffinized with xylene, and dehydrated in water through 
graded ethanol. For PAS staining, the kidney section was incubated in 0.5% periodic 
acid solution for 10 minutes, Schiff reagent for 15 minutes, and then was 
counterstained with Weigert’s hematoxylin for 30 seconds. After the staining, the 
kidney sections were rehydrated in water through graded alcohol, cleaned, and 
mounted with Permount. 
 
Mesangial Index. In order to establish what percent of glomerular area is occupied 
by mesangial matrix, we took a sufficient number of images at 40x magnification to 
ensure a minimum of 25 glomeruli per animal were represented.  The mesangial 
index quantification was described as before29. In brief, ImageJ was used to set a 
minimum HSI (hue, saturation, intensity) threshold according to PAS-positive 
material which if exceeded would count as mesangial matrix.  The software was 





Cell culture. Primary mouse mesangial cells were isolated from glomeruli of 6 to 8 
weeks old miR-21 WT and KO mice as described before30,31. In brief, mouse 
kidneys were harvested. Cortex was removed from medulla, cut into 1mm cube, and 
past through a series of cell strainers from 200μm, 100μm to 70μm. At last, 
glomeruli were collected on the 70μm cell strainer and digested in collagenase A 
solution (1mg/ml) for 30 minutes. The digested glomeruli were then cultured in 
collagen type I-coated 6cm dish for 3 to 5 days. Once the mesangial cell clusters 
were formed, they were subcultured and kept propagating. The experiments were 
performed in PMC between 5 to 15 passages. The cells were cultured in RPMI 1640 
medium supplemented with 20% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, and 1% insulin-transferrin-selenium (Invitrogen) and were 
incubated in 37°C, 5% CO2 incubator. 
  
Proliferation assay. PMC were trypsinized and cell number was counted using 
trypan blue exclusion method including trypan blue solution 0.4% (invitrogen) and 
haemocytometer per manufacturer’s protocol. The miR-21 WT and KO PMC were 
grown in a 96 well plate at the same cell number for 5 repeats. After 24 hours of cell 
growth in 10% FBS, cell proliferation was examined by MTT (Tetrazolium dye) cell 




Cell cycle distribution measurement. PMC were serum-starved (0.2%) for 24 
hours and shifted to 10% FBS with or without TGFβ treatment (10ng/ml). After 
another 20 hours, the cells were harvested and fixed in 70% ethanol. Cell cycle 
distribution was determined by staining the cells with propidium iodide and 
examining the staining intensity in flow cytometry as described32.  
 
Statistical analysis 
Proteinuria, mesangial index and picro-sirius staining intensity were compared 
between miR-21 WT and KO mice using t-test. The cell proliferation and cell cycle 






















Figure 3.1. Examination of blood sugar in STZ-treated miR-21 WT, HET and 
KO mice at 0, 2, 6, 12, 20 weeks after STZ treatment. There is no blood glucose 
















































Figure 3.2. Examination of proteinuria in STZ-treated miR-21 WT, HET and 
KO mice at 0, 4, 8, 12, 16, 20 weeks after STZ treatment. (N=5 to 8 in each 

































































Figure 3.3. Examination of kidney histology by PAS staining in STZ-treated 
miR-21 WT, HET and KO mice. (A) PAS staining showed increased deposition of 
PAS in glomeruli of STZ-treated miR-21 KO compared to treated miR-21 WT mice. 
(B) Histogram and statistical analysis of mesangial index (%) calculating from PAS 
staining showed significantly higher mesangial expansion in glomeruli of 
STZ-treated miR-21 KO (N=5) versus treated miR-21 HET or WT mice (N=5 for 
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Figure 3.4. Examination of cell migration in miR-21 WT and KO PMC. The 
scratch-wound assay showed that miR-21KO PMC had significantly higher ability 























0 hr 24 hr 48 hr 0 hr 24 hr 48 hr 
miR-21 WT 


















Figure 3.5. Examination of cell proliferation/viability in miR-21 WT and KO 
PMC. The MTT cell proliferation assay indicated that miR-21 KO PMC had 
significant higher MTT absorbance or more cells than miR-21 WT PMC after 24 







































Figure 3.6. Examination of cell cycle distribution in miR-21 WT and KO PMC 
at 20 hours after 10% FBS supplement. In flow cytometry, the propidium iodide 
staining showed that miR-21 KO PMC had significantly more cells in S phase than 


































Figure 3.7. Examination of potential regulatory genes of miR-21 in in glomeruli 
of STZ-treated miR-21 WT and KO mice. The qrt-PCR result showed that there 
was an increased expression of Cdk6 and Cdc25a in glomeruli of STZ-treated 
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Figure 3.8. Examination of the protein level of PTEN in miR-21 
mimic-transfected human embryonic kidney (HEK) cells and DBA/2J mice. (A) 
The western blot showed that the protein level of PDCD4 was decreased by miR-21 
overexpression in HEK cells. However, there was no difference in the protein level 
of PTEN between miR-21mimic- and scramble-transfected HEK cells. (B) The 
western blot showed that there was no difference in the protein level of PTEN and 
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miRNAs regulate gene expression on a post-transcriptional level by binding to the 
primary transcript of target genes, thereby repressing translation into protein and 
facilitating degradation. Because experimental identification of target genes remains 
challenging, different computational algorithms have been developed to predict 
miRNA-mRNA interactions. Unfortunately, overlap between different algorithms 
and prediction accuracy for specific cell types and disease contexts are poor. 
Therefore, we developed a new algorithm to identify miRNA-mRNA interaction 
based on associations of expression with disease clinical manifestation. 
To test this algorithm, we used miRNA and mRNA expression data obtained from 
the same micro-dissected glomeruli of kidney biopsies of American Indian patients 
with DN (testing and validating cohorts, total n=48). The miRNA and mRNA 
expression levels were correlated independently with patients’ urine albumin to 
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creatinine ratio (ACR). ACR-associated miRNAs and mRNAs were integrated with 
two computational prediction algorithms and experimental results from 
Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation 
(PAR-CLIP) RNA sequencing. We determined that among 10 miRNAs, which were 
highly correlated with ACR (P < 0.0001, R > 0.6), 6 showed high expression in renal 
glomeruli and are broadly conserved. 245 transcripts of protein-coding genes were 
correlated with ACR (P < 0.0001, R > 0.4 or < -0.4). Among them, 25 transcripts had 
been found to be candidate targets for at least one of the ACR-associated 6 miRNAs 
by two prediction algorithms and PAR-CLIP RNA sequencing. We further determined 
that overexpression of miR-200a repressed RALGPS2, SUPT6H and EXOC7 mRNA 
levels and that the 3’UTR of EXOC7 is a sequence-dependent target of miR-200a. 
We propose that integrating phenotype-associated miRNA and mRNA expression with 
experimental and computational target identification methods facilitates 









Mature miRNAs, with RNA-induced silencing complex (RISC), bind to 
complementary sequences of mRNA 3’UTR to repress the mRNA expression at a 
post-transcriptional level1,2. The exact repression mechanism, though explored, is still 
unclear but it is involved in mRNA deadenylation, decapping and translational 
ribosomal inhibition3,4. Lately, miRNAs have also been shown to bind to mRNA 
5’UTR and coding region to repress the mRNA expression5-8. miRNA are critical in 
maintaining normal cell physiology and regulating disease pathogenesis9,10. The 
expression of miR-17-92 cluster targets hundreds of genes and is strongly associated 
with oncogenic activity11. On the other hand, depletion of miR-17-92 in mice is 
postnatal lethal and leads to cardiac and lung defects12. Therefore, a significant 
number of studies have investigated the interaction and targeting between miRNAs 
and mRNAs. To date, several algorithms are available to predict the targeting between 
miRNAs and mRNAs, such as TargetScan13-15, which is based on the matched seed 
sequences and conservative binding sites. MiRNAanda 16,17, which applies dynamic 
programming alignment and thermodynamic calculation for complimentary binding 
between miRNAs and mRNAs, is another commonly used application. However, the 
false prediction rate for those prediction algorithms remains high18 and the number of 
experimentally-verified targets is still low. For example, human miR-21 has only 42 
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validated target genes according to miRNAecord19, a resource of 
experimentally-verified miRNA-target interaction, but it has 164 predicted targets in 
Targetscan 13-15. 
For that reason, many studies developed new approaches to explore miRNA-mRNA 
interaction more than just sequence binding prediction. That includes MAGIA20, 
which integrates miRNA-mRNA correlation from the expression data with 
pre-existing prediction algorithms. The other tools apply new regression models21,22 
or Bayesian inference23 to facilitate target genes searching. Nevertheless, it is still 
unclear whether these approaches improve the preciseness to identify target genes or 
determine the regulatory role of miRNA-mRNA interaction in disease progression. 
Therefore, we developed an alternative approach to investigate miRNA-mRNA 
interaction based on their associations with disease clinical manifestation. 
We previously had identified miRNAs that exhibit high correlation with ACR, a 
disease relevant outcome. We noticed that current knowledge about potential 
functions of these miRNAs remains very limited and the number of potential target 
genes predicted by computational algorithms is very large. To facilitate identification 
of mechanisms regulated by ACR-associated miRNAs, we developed an in-silico 
approach to link disease-associated miRNAs and disease-associated genes together, 
based on the correlation with disease clinical manifestation, to uncover 
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disease-relevant target genes. With this approach, we identify miRNAs target genes as 





miRNAs correlate with proteinuria in human diabetic nephropathy 
To identify miRNAs relevant for glomerular injury, we profiled the miRNA 
expression from renal glomeruli of kidney biopsies of 48 American Indian DN 
patients. To identify miRNAs with potential mechanistic relevance, we associated 
glomerular miRNA expression levels with clinical relevant manifestations, such as 
urine ACR or GFR in our cohorts. The participants exhibited a broad range of 
proteinuria (quantified as ACR in μg/mg), while the mean GFR (iothalamate 
clearance) was above 90 ml/min/1.73m2 (Table 4.1). Highly significant and positive 
correlations with ACR were detected for 49 miRNAs out of 377 (P < 0.0001, R > 0.4). 
Interestingly, none of the tested miRNAs exhibited significant negative correlation 
with ACR. Moreover, we did not notice significant correlation between miRNAs and 
GFR (P-value > 0.05 for all miRNAs). We listed the top 10 miRNAs, which had the 
most positive correlation with ACR (Table 4.2). Because highly abundant miRNAs 
are in general thought to be more likely to mediate significant target gene repression, 
we ranked the miRNAs by their relative expression level in renal glomeruli and 
identified the broadly-conserved miRNAs24,25. We chose 6 miRNAs, miR-21, 
miR-135a, miR-200a, miR-218, miR-429, and miR-142-3p that are both 
highly-expressed in renal glomeruli and broadly-conserved cross species to identify 
112 
 
miRNA-mediated mechanisms of DN.  
 
Most miRNA-correlated genes are not predicted targets of miRNAs 
To identify candidate miRNA-mRNA interaction, the mRNA from the same renal 
glomeruli of kidney biopsies of the same American Indian cohorts was profiled. The 
correlation analysis was performed between the 6 miRNAs and genes on the array. 
Table 4.3 listed the top 10 genes that had the most negative correlation (R ranges from 
-0.48 to -0.67) with each 6 miRNAs. Figure 4.1 illustrated the correlated connection 
between miRNAs and genes. Among 44 top 10 miRNA-correlated genes, only 
ANTXR2 and IFNAR1 (4.5%) are predicted as sequence-dependent targets of 
miRNA218 and miRNA200a based on targetscan13-15, respectively. If we expand the 
number up to the top 50 most miRNA-correlated genes, 7 out of 194 correlated genes 
are targetscan predicted targets (3.6%), and among the top 100 most 
miRNA-correlated genes, 19 out of 349 correlated genes are targetscan predicted 
targets of the corresponding miRNA (5.4%). 
 
ACR-correlated genes are ACR-correlated miRNAs’ predicted targets 
To test our hypothesis that miRNA expression is driven by disease status to negatively 
feedback the change of disease-associated genes. We correlated mRNA expression 
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with disease clinical manifestation, ACR. The result showed that 245 mRNAs 
significantly correlated with ACR (R > 0.4 or R < -0.4, P < 0.0001). Among those 245 
genes, 39 genes (16%) are the TargetScan-predicted targets for the previous chosen 6 
miRNAs (Table 4.4). We additionally examined whether there were RNA read 
clusters in those 39 genes 3’UTR by PAR-CLIP RNA sequencing in human 
embryonic kidney (HEK) cells26. We also applied the second prediction algorithm, 
miRNAanda16,17, to further verify the possible miRNAs’ targets. We found that 25 out 
of the 39 genes had RNA read clusters in 3’UTR and at the same are predicted as the 
corresponding miRNA’s targets in miRNAanda. Figures 4.2 illustrated the target 
predictions between the chosen 6 ACR-correlated miRNAs and ACR-correlated genes 
that both have RNA read clusters in 3’UTR and are predicted targets of the 
corresponding miRNA’s by two prediction algorithms, TargetScan and miRNAanda. 
We regarded those 25 genes as the most likely targets of the corresponding miRNAs 
and the interaction with miRNAs might play a role in disease progression. 
To further understand the relationship between those 25 genes and their predicted 
miRNAs, we examined their associations from the miRNA and mRNA expression 
data by Pearson correlation (Table 4.5). The result showed that the correlation 
between the most likely targets and their predicted miRNAs was moderate (R ranges 
from -0.17 to -0.45 and 0.05 to 0.37) and less than 50% of the correlation was 
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significant (P < 0.05). Moreover, the 25 genes did not rank high according to the most 
negative or positive correlation. 
 
miR-200a has repression effect on SUPT6H and EXOC7 
miR-200a is known to regulate epithelial-mesenchymal transition (EMT)27 and is 
implicative to protect against DN28. To verify the potential targets that were identified 
by linking ACR-correlated miRNAs and genes, we proceeded to demonstrate the 
targeting between miR-200a and its potential targets. Among miR-200a potential 
targets, we chose the top 3 most positively-correlated genes, RALGPS2, LYPD6, 
AGPS, and top 3 most negatively-correlated genes, NFASC, SUPT6H, EXOC7, to 
perform the experimental validation.  
To identify a suitable cell system to test candidate miR-200a target genes, we first 
examined the endogenous miR-200a level in different cells. Our qrt-PCR result 
showed that HEK cells had very low endogenous miR-200a compared to podocyte 
and renal proximal tubular cell lines (Figure 4.3). ZEB2 is a known target of 
miR-200a27. Consequently, we measured ZEB2, RALGPS2, LYPD6, AGPS, SUPT6H, 
EXOC7, and NFASC mRNA level by transfecting miR-200a mimic into HEK cells. 
The qrt-PCR result revealed that the miR-200a mimic-transfected HEK cells had 
significantly lower ZEB2, RALGPS2, SUPT6H and EXOC7 level compared to the 
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miR-200a scramble transfection (P < 0.01; Figure 4.4A: fold change for ZEB2, 
SUPT6H, EXOC7 were 0.23, 0.74 and 0.75, respectively. Figure 4.4B: fold change 
for RALGPS2 was 0.59). 
 
EXOC7 is a target gene of miR-200a 
To confirm direct targeting of EXOC7 by miR-200a, we co-transfected HEK cells 
with EXOC7 3’UTR luciferase construct and miR-200a mimic oligonucleotides. The 
results demonstrated decreased luciferase activity upon transfection of miR-200a 
mimic (Figure 4.5; P < 0.01), confirming direct targeting of the 3’UTR of EXOC7 by 





In this study, we identified miRNAs and mRNAs in renal glomeruli that exhibit 
significant correlation with ACR in patients with DN. We further discovered that 
many ACR-correlated genes are predicted targets of ACR-correlated miRNAs by two 
different prediction algorithms and PAR-CLIP RNA sequencing. We verified that 
EXOC7 are the sequence-dependent target of miR-200a, and RALGPS2 and SUPT6H 
are regulated by miR-200a. This approach, linking miRNAs and genes by their 
associations with disease status, provide an alternative way to identify miRNA target 
genes.  
Among the top 10 miRNAs that had the most positive correlation with ACR, 6 were 
highly-expressed in renal glomeruli and broadly conserved. Some of the significant 
miRNAs were widely studied in cancer biology. For instance, miR-135a promotes 
growth and migration of cancer cells29,30, while miR-218 limits the invasiveness of 
cancer cells31, and miR-142-3p regulates myeloid differentiation and leukemia 
development32. Nevertheless, there are miRNAs related to kidney diseases, such as 
miR-21, which plays a role in renal fibrosis33,34. Furthermore, our previous study 
showed that miR-21 protects against TGFβ-related renal glomerulopathy. In addition, 
miR-200a and miR-429, which all belong to the miR-200 family, have been shown to 
regulate EMT and prevent renal fibrosis27,28.  
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To identify the target genes of ACR-correlated miRNAs, we correlated the miRNA 
and mRNA expression from the same samples. Interestingly, we did not find many 
predicted targets from the negative correlation of mRNAs with miRNAs (Table 4.3). 
We further correlated genes with ACR, and unexpectedly found that many 
ACR-correlated genes (both positive and negative correlation) are the predicted 
targets of the ACR-correlated miRNAs (Table 4.4). However, we also noticed that the 
correlations between the ACR-correlated miRNAs and their target-predicted 
ACR-correlated genes are less significant (Table 4.5). As studies have observed that 
miRNAs can form negative feedback loop in the signaling pathway35,36, miRNAs 
might go up with disease progression as an attempt to limit the disease damage. Under 
this concept, for the miRNA-targeted genes that increase with disease progression 
(positive correlation with ACR), miRNAs will also increase as an attempt to repress 
the upregulation. For that reason, we observed many ACR positively-correlated genes 
are predicted targets of miRNAs (Table 4.4). However, due to the negative feedback 
cannot completely reverse the original change, we did not detect significant negative 
correlation between miRNAs and their targets from miRNAs and mRNA expression 
data (Table 4.5). 
We additionally noticed that many ACR negatively-correlated genes are also predicted 
targets of miRNAs (Table 4.4). Based on this observation, we proposed another 
118 
 
mechanism that genes decrease as a consequence of progression of disease. This 
concept suggests that miRNAs mediate additional gene repression. This positive 
enforcement regulation loop was also observed in previous studies36. Due to the 
negatively-correlated genes are directly driven by the disease itself and miRNAs 
targeting only contributes to additional repression, we did not detect very significant 
negative correlation between the ACR-correlated miRNAs and their predicted targets, 
which are negatively correlated with ACR. Importantly, we did not detect miRNAs 
that were negatively correlated with ACR. This is consistent with our hypotheses that 
miRNAs increase with disease progression to limit disease-upregulated genes or 
miRNAs increase with disease progression to further repress the 
disease-downregualted genes.  
Since miR-200a is highly correlated with ACR and together with miR-429, which also 
belongs to miR-200 sequence family, suppresses EMT to protect against renal 
fibrosis27,28, we chose miR-200a to verify the finding from linking the ACR-correlated 
miRNAs and ACR-correlated genes. Among 245 genes, which are associated with 
ACR, 10 of them are the targetscan-predicted targets of miR-200a (Table 4.4). The 
basic functions of those genes were studied. NFASC (neurofascin) is a cell adhesion 
molecule, which links extracellular matrix to the intracellular cytoskeleton, and plays 
a role in neuron growth during development37. EXOC7 (exocyst complex component 
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7) is the component of exocytosis complex and it is involved in the docking of 
exocytic vesicles with fusion sites on the plasma membrane38. EXOC7 is required for 
targeting glucose transporter 4 (Glut4) to the plasma membrane in response to 
insulin39. RALGPS2 (Guanine nucleotide exchange factor for the small GTPase 
RALA) plays a role in cytoskeleton organization40. In addition, SUPT6H (suppressor 
of Ty 6 homolog), ZNF629 and ZNF793 (zinc finger protein) regulates gene 
translation41,42. Although these genes have not been broadly studied in DN, the new 
miRNA-mRNA interactions we are proposing here bring a new prospect to DN 
disease mechanism. Exocytosis forms the basis of the delivery of secretory proteins 
and intracellular signaling, such as insulin secretion as well as the cellular response to 
inuslin43. Reduced insulin exocytosis in human pancreatic β cells is related type 2 
diabetes44 and diabetes also affects the ability of exocytosis in other cells45. 
Furthermore, Exocytosis is involved in aquaporin 2 water channel activity in renal 
collecting tubule46 and has a role in renal ischemia-reperfusion injury47. Our result, 
which showed EXOC7 being the target of miR-200a, provides additional evidence 
that miR-200a and exocytosis might play an important role in DN, and it urges 
additional studies to explore these intriguing findings.  
Despite our result that miR-200a regulates SUPT6H and EXOC7, compared to the 
well-known target of miR-200a, ZEB227, the repression effect of miR-200a on 
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EXOC7 and SUPT6H seems marginal (fold change ≈ 0.7; Figure 4.4A). Nevertheless, 
miRNAs can have tuning interactions with genes to marginally repress the protein to 
the target level1. For example, miR-375 targets myotrophin to lower its level to an 
optimal level but still remains functional for insulin secretion48. miR-8 in Drosophila 
reduces atrophin to a level to prevent neurodegeneration without compromising 
viability49.  
Our concepts that miRNAs increase with disease progression to limit gene 
upregulation or to further repress gene downregulation can effectively narrow down 
the potential miRNA targets among hundreds of candidates. Nevertheless, our method 
to link disease-associated miRNA and disease-associated mRNA needs to be 
accompanied by prediction algorithms or other supporting experiments, such as 
PAR-CLIP RNA sequencing. Therefore, to effectively identify miRNA’s 
sequence-dependent targets, we proposed creating a ranking system by using disease 
associations with miRNAs and mRNA plus prediction algorithms and the interaction 
with AGO proteins.  
In summary, we have shown linking disease-associated miRNAs and 
disease-associated mRNA by target prediction is an alternative way to identify 
miRNA-mRNA interaction. The findings that miR-200a targets EXOC7 and other 
genes open up potential disease mechanisms to be explored in the future. 
121 
 
Methods and Materials 
Study Subjects. The kidney biopsy samples had been collected from enrolled 
participants in a randomized, placebo-controlled, clinical trial (ClinicalTrials.gov No. 
NCT00340678) as the previous chapter described50. Urinary albumin and creatinine 
as well as iothalamate concentrations for GFR determination were measured as 
described51 and values of the examination closest to the kidney biopsy were used in 
the present analyses. This study was approved by the Review Board of the National 
Institute of Diabetes and Digestive and Kidney Diseases. Each participant gave 
informed consent. 
  
miRNA expression analysis. miRNA profiling was obtained using TaqMan miRNA 
assays (Applied Biosystems) as described52. In brief, small RNA fraction (<200 nt) 
was isolated from micro-dissected glomeruli using RNeasy® and MinElute® 
Cleanup kits (Qiagen) and reverse transcribed using TaqMan Megaplex RT primers 
(Applied Biosystems). Human glomerular small RNA was amplified by Megaplex 
PreAmp primers (Applied Biosystems). TaqMan array human and rodent miRNA ‘A’ 
cards (Applied Biosystems) were used to obtain miRNA profiles according to the 
manufacturer’s protocol. miRNA expression values, threshold cycle (CT), were 
normalized by U6 small nuclear RNA (snRNA), and RNU44 and RNU48 small 
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nucleolar RNA (snoRNA). Delta cycle time (ΔCT) was calculated by subtracting 
miRNAs’ CT from geometric mean of snRNA’s and snoRNA’s CT. Expression level 
in arbitrary units were calculated from 2 to the power of delta cycle time (2ΔΔCT). 
 
mRNA microarray and analysis. Total RNA was isolated from micro-dissected 
glomeruli of kidney biopsy according to a protocol, which was described before53. 
The total RNA was reverse-transcribed and linearly amplified to be applied to 
Affymetrix HG-U133A microarray. The fragmentation, hybridization, staining and 
imaging were performed by the Affymetrix Expression Analysis Technical Manual. 
The microarray analysis was described before and Robust Multichip Average (RMA) 
was used to normalize the data54. 
 
Batch correction. Our study cohort consisted of one testing cohort (N=22) and one 
validating cohort (N=26). Subjects of both cohorts tested in this study were pulled 
from the same pool of participants of the American Indian study. In order to increase 
analysis power, we combined miRNA or mRNA expression data from two cohorts to 
increase sample size (total subjects = 48). We applied ComBat55, a method of 




Correlation analysis. Pearson correlation was performed in the correlation analysis. 
miRNA ΔCT was correlated with mRNA hybridization log2 transformed intensity, 
mRNA hybridization log2 transformed intensity was correlated with patient’s urine 
albumin-creatinine ratio (ACR), and arbitrary fold change of miRNAs, which was 
calculated from 2 to the power of ΔCT, was correlated with patient’s ACR. 
 
Photoactivatable Ribonucleoside Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP). Argonaute proteins (AGO) 1-4, which are the 
component of RISC and bind to both miRNAs and mRNA, were 
immunoprecipitated to examine the binding RNA fragments. The PAR-CLIP method 
was used and described as previous26. In brief, HEK cells stably expressing 
FLAG/HA-tagged AGO1-4 were grown overnight in the medium supplemented with 
100 μM 4-thiouridine (4-SU), which is photoactivatable nucleosides. The living 
cells were irradiated with 365 nm UV light to introduce crosslinking between the 
AGO1-4 and RNA. Then, the AGO 1-4 were immunoprecipitated and the binding 
RNA with the AGO1-4 was recovered to cDNA library to be Solexa deep sequenced. 
 
miRNA transfection. miR-200a mimic oligonucleotides (Thermo Scientific 
Dhamacon miRNAIDIAN microRNA Mimics) were applied with Lipofectamine® 
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RNAiMAX Reagent (Invitrogen) to transfect HEK cells. The cell transfection was 
processed per manufacturer’s protocol. 
 
Quantitative real-time PCR. Qrt-PCR for measuring mRNA levels were conducted 
using TaqMan validated primers and probe sets (Applied Biosystem), according to 
manufacturer’s protocols, on an ABI 7900HT real-time PCR system. 
  
Luciferase reporter assays. The full length EXOC7 3’UTR was constructed with 
firefly luciferase (abm, BC, Canada). The 3’UTR vector, Renilla luciferase plasmid, 
and miR-200a mimic oligonucleotides were co-transfected into HEK cells using 
lipofectamine LTX and plus reagents (Invitrogen). Luciferase activity was measured 
48 hours after transfection in luciferase assay plate reader. 
 
Statistical analysis. The correlation analysis and significance was determined by 
Pearson correlation and R script was used. T-test was used to compare mRNA level 




Table 4.1. Characteristics of American Indian cohort 
 American Indian 
No. of subject 48 
Age: Mean (SD) 44.4 (10.2) 
Gender: % of female 81% 
GFR: Mean (SD) 149.2 (50.6) 












Table 4.2. The top 10 ACR-correlated miRNAs 
miRNA Correlation P value Relative expression*  Broadly conserved miRNA 
miR-642 0.75 <0.0001 medium no 
miR-21 0.71 <0.0001 high yes 
miR-135a 0.69 <0.0001 medium yes 
miR-32 0.69 <0.0001 low no 
miR-142-5p 0.69 <0.0001 low no 
miR-660 0.67 <0.0001 medium no 
miR-200a 0.67 <0.0001 medium yes 
miR-218 0.66 <0.0001 medium yes 
miR-429 0.62 <0.0001 medium yes 
miR-142-3p 0.62 <0.0001 high yes 
*Expression level was defined as high if cycle time value in real-time PCR <25, as medium if cycle 
time value in real-time PCR ranges from 25-30, as low if cycle time value in real-time PCR >30         




Table 4.3. Correlation between genes and ACR-correlated miRNAs* 
miRNA Correlated gene Correlation miRNA Correlated gene Correlation miRNA Correlated gene Correlation 
miR-21 PDIA5 -0.58 miR-135a IFNAR1 -0.60 miR-200a ANTXR2 -0.67 
miR-21 FAM53B -0.51 miR-135a ANTXR2 -0.60 miR-200a HYAL2 -0.65 
miR-21 ROBO4 -0.50 miR-135a GNA12 -0.59 miR-200a LMO2 -0.64 
miR-21 ASCC2 -0.50 miR-135a PTPRG -0.59 miR-200a AMMECR1L -0.64 
miR-21 STARD8 -0.50 miR-135a GCC1 -0.58 miR-200a ETS2 -0.64 
miR-21 RNF151 -0.50 miR-135a TICAM2 -0.56 miR-200a SEC14l1 -0.63 
miR-21 HTRA3 -0.50 miR-135a MAP7D1 -0.55 miR-200a IFNAR1† -0.63 
miR-21 UBE2J2 -0.49 miR-135a SFRS16 -0.54 miR-200a S1PR1 -0.62 
miR-21 S1PR1 -0.49 miR-135a PDIA5 -0.53 miR-200a ARRB1 -0.62 
miR-21 ID1 -0.49 miR-135a GOLGA3 -0.53 miR-200a GFOD1 -0.62 
miR-218 BAZ2A -0.61 miR-429 SNX11 -0.56 miR-142-3p PDIA5 -0.60 
miR-218 PLXND1 -0.61 miR-429 GNA12 -0.55 miR-142-3p RNF151 -0.55 
miR-218 ANTXR2† -0.61 miR-429 ANTXR1 -0.55 miR-142-3p SNX11 -0.53 
miR-218 TNFRSF1A -0.60 miR-429 TBCD -0.55 miR-142-3p ROBO4 -0.53 
miR-218 MINK1 -0.59 miR-429 SH3BP5 -0.54 miR-142-3p NUFIP1 -0.50 
miR-218 TICAM2 -0.59 miR-429 ANTXR2 -0.54 miR-142-3p CARHSP1 -0.50 
miR-218 OSBPL5 -0.58 miR-429 NUDT11 -0.54 miR-142-3p STARD8 -0.50 
miR-218 SETD8 -0.57 miR-429 CHFR -0.54 miR-142-3p ID1 -0.49 
miR-218 MAP7D1 -0.57 miR-429 EDG1 -0.54 miR-142-3p HTRA3 -0.48 
miR-218 TOX2 -0.57 miR-429 CYP26B1 -0.53 miR-142-3p EML1 -0.48 
The P value for correlation is all < 0.0001 
*Table only lists the top 10 genes that have the most negative correlation with miRNAs 










targeting the gene* 
miRanda-predicted 
targeting between 
gene and miRNA 





yes miR-21, miR-200a, miR-429 yes 
VPS37C -0.47 yes miR-135a yes 
SUPT6H -0.47 yes miR-135a, miR-200a yes 
UBOX5 -0.45 yes miR-135a yes 
NAIF1 -0.44 yes miR-135a yes 




















yes miR-135a, miR-200a yes 
NFASC -0.59 yes miR-200a, miR-429 no 
EXOC7 -0.53 yes miR-200a yes 
ZNF793 -0.45 yes miR-200a yes 
ARHGEF18 -0.42 yes miR-200a yes 
RBM33 -0.41 yes miR-200a yes 





yes miR-200a yes 
RIMS3 -0.53 yes miR-218, miR-429 no 
ZNFX1 -0.46 yes miR-218 no 
FLNC -0.44 no miR-218 yes 
ARL3 -0.44 yes miR-218, miR-429 yes 
SH3TC2 -0.42 no miR-218 no 
OLA1 -0.42 yes miR-218 yes 
N4BP1 -0.42 yes miR-218 no 






























yes miR-218 yes 
SYDE1 -0.51 no miR-429 yes 
PI4KB -0.44 yes miR-429 yes 
FYN -0.44 yes miR-429 yes 
FXR2 -0.43 yes miR-429 yes 
ZFYVE1 -0.42 yes miR-429, miR-142-3p no 
SP8 -0.46 yes miR-142-3p yes 
SH2B1 -0.43 no miR-142-3p yes 
* The target prediction is based on targetscan prediction algorithm. The P value for correlation between 
gene and ACR is all < 0.0001. Bold font indicates genes that have RNA cluster in 3’UTR in PAR-CLIP 
data and are predicted targets of the corresponding miRNAs in targetscan and miRanda 
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Table 4.5. Correlation between ACR-correlated miRNAs and their target-predicted 





Correlation P value Correlation 
ranking* 
miR-21 EHD1 -0.31 0.03 584 
miR-21 RALGPS2 0.34 0.02 208 
miR-135a VPS37C -0.17 0.27 4249 
miR-135a SUPT6H -0.21 0.17 3097 
miR-135a UBOX5 -0.23 0.12 2494 
miR-135a NAIF1 -0.45 0.002 93 
miR-135a RARA -0.32 0.03 972 
miR-135a AGPS 0.19 0.2 2221 
miR-200a EXOC7 -0.30 0.04 2172 
miR-200a SUPT6H -0.33 0.02 1646 
miR-200a ZNF793 -0.23 0.13 3920 
miR-200a ARHGEF18 -0.23 0.12 3803 
miR-200a RBM33 -0.35 0.02 1400 
miR-200a AGPS 0.22 0.14 2042 
miR-200a LYPD6 0.12 0.44 3627 
miR-218 ARL3 -0.20 0.18 3276 
miR-218 RARA -0.30 0.04 1415 
miR-218 OLA1 -0.29 0.05 1612 
miR-218 ABCC4 0.31 0.04 934 
miR-218 SLC12A2 0.06 0.68 5420 
miR-218 SYPL1 0.26 0.09 1510 
miR-218 L3MBTL4 0.37 0.01 433 
miR-218 FAM5C 0.21 0.17 2251 
miR-218 EGLN3 0.33 0.03 725 
miR-429 PI4KB -0.33 0.02 773 
miR-429 FYN -0.30 0.04 1154 
miR-429 ARL3 -0.25 0.09 2109 
miR-429 FXR2 -0.29 0.05 1349 
miR-142-3p SP8 -0.27 0.07 910 
miR-142-3p SYPL1 0.05 0.72 4877 
*The gene was ranked by the most negative or positive correlation with the corresponding miRNA 
Bold font indicates genes that have RNA cluster in 3’UTR in PAR-CLIP data and are predicted targets 





Figure 4.1. Cytoscape illustration of correlation between ACR-correlated 
miRNAs and genes in the same American Indian cohort. The 6 chosen 
ACR-correlated miRNAs are in gray round rectangle node. Top 10 genes that have the 
most negative correlation with each ACR-correlated miRNAs are in white and black 
circle node and have black straight edge connecting to the negatively-correlated 
miRNAs. Among them (N=44), only two are targetscan-predicted targets of miR-200a 







Figure 4.2. Cytoscape illustration of the target prediction between 
ACR-correlated miRNAs and ACR-correlated genes. ACR-correlated genes (white 
circle: negative correlation ith ACR; white diamond: positive correlation with ACR) 
are predicted targets of their connected ACR-correlated miRNAs (gray round 
rectangle) in targetscan. The targetscan-predicted targets also have RNA cluster in 
3’UTR in PAP-clip data and are predicted as the corresponding miRNA targets in the 











Figure 4.3. Examination of miR-200a level in different cell lines. Quantitative real 
time-PCR showed relatively low endogenous miR-200a level in human embryonic 
kidney (HEK) cells compared to human podocyte cell lines and human renal proximal 





























































Figure 4.4. Examination of the predicted target between miR-200a and selected 
ACR-correlated genes. (A) Quantitative real time-PCR showed that miR-200a 
mimic transfection significantly suppressed ZEB2, SUPT6H and, EXOC7 mRNA 
levels in human embryonic kidney (HEK) cells (*P < 0.01, fold change for ZEB2, 
SUPT6H, EXOC7 were 0.23, 0.74 and 0.75, N=5). There is no repression effect of 
miR-200a mimic on NFACS. (B) Quantitative real time-PCR showed that miR-200a 
mimic transfection significantly suppressed RALGPS2 mRNA levels in human 
embryonic kidney (HEK) cells (*P < 0.01, fold change for RALGPS2 was 0.59, N=3). 
























A. miR-200a scramble transfection 



















































Figure 4.5. Examination of direct target between EXOC7 and miR-200a. 
Luciferase assay of HEK cells co-transfected with EXOC7 3’UTR luciferase 
construct and miR-200a mimic oligonucleotides showed that there was a decreased 











































miR-200a scramble transfection 
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Conclusions and future directions 
 
Conclusions 
CKD is an important public health issue consuming a significant portion of medical 
resources and has limited options for effective treatment. To prevent development and 
progression of CKD, new targets for intervention need to be identified and it requires 
better understanding of the underlying mechanisms. DN accounts for more than 40% 
of new cases of ESRD in the United States1. Despite significant improvement made 
for understanding the mechanism for DN, current interventions have limited success.  
 
TGFβ is a cytokine that mediates the progression of DN and other types of kidney 
disease. Because TGFβ is a multi-functional cytokine that also exhibits protective 
effects after renal injury including limiting the inflammatory response2, inhibition of 
TGFβ itself harbors significant complications. Thus, it is critical to identify new 
therapeutic targets other than TGFβ. 
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Recent data suggest a mechanistic involvement of miRNAs in the progression of DN 
as well as other kidney diseases3-6. To identify candidate miRNAs that may mediate 
glomerular injury in human DN, we quantitatively determined miRNA expression in 
the glomeruli of patients with DN and examined the association of miRNAs with 
relevant clinical outcomes. Our analysis uncovered that the expression of miR-21 in 
glomeruli was highly associated with the severity of glomerulopathy. miR-21 is 
known to regulate TGFβ signaling activity7,8 and has been shown to promote fibrosis 
after tubular injuries kidney3-6. However, the role of miR-21 in glomerular injury has 
not been examined and the function of miR-21 has been shown to be cell 
type-specific9. Therefore, we questioned whether miR-21 plays a different role in 
glomerular injury. We interrogated this question by examining the impact of loss of 
miR-21 on two mice models of glomerulopathy, TGFβ1 transgenic mice and 
STZ-induced diabetic mice in which the expression of miR-21 increases early 
during disease development. 
 
In TGFβ1 transgenic mice, we determined that loss of miR-21 resulted in accelerated 
glomerular injury and loss of podocytes. We also found that miR-21 inhibits 
podocyte apoptosis in vivo and in vitro. Furthermore, we showed that miR-21 
represses the activity of multiple TGFβ-regulated pro-apoptotic pathways. In 
141 
 
STZ-induced diabetic mice, miR-21 appeared to inhibit cell cycle regulators, Cdk6 
and Cdc25a, to inhibit mesangial expansion. These findings suggest that miR-21 
mediates cell type-specific functions in the kidney. 
  
Through our investigations, we suggest that miRNAs exhibit specific functions in 
glomeruli through the repression of disease relevant mRNAs. Computational 
algorithms for predicting targets of miRNAs were widely used. However, due to the 
lack of preciseness of the prediction, new methods are still needed to guide 
mechanistic studies. Therefore, we developed a novel approach integrating 
disease-associated miRNAs and mRNAs with target predictions. We determined that 
miR-200a, which has been implicated as a regulator of DN, represses the expression 
of EXOC7, RALGPS2, and SUPT6H. These newly identified target genes of 
miR-200a may constitute novel regulators of DN.  
 
This work has identified a novel role of miR-21 in glomerular injury and developed 
a new approach, which is based on the association of miRNAs and mRNAs with 
specific disease phenotypes, to identify candidate miRNA targets. These findings 
provide new directions for future research projects. Here, we elaborated on the 
conclusion from this body of work and discussed the perspectives of the possible 
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future projects aiming at determining the cell-type specific role of miR-21 and the 
regulatory role of other miRNAs in DN.  
 
miRNAs and human DN 
Significant differences in gene expression have been observed between patients with 
DN and murine models of DN10. Therefore, we determined the expression of 
miRNA in patients with DN. Interestingly, we found that the expression of several 
miRNAs, such as miR-21 and miR-200a, was positively correlated with the levels of 
proteinuria of patients with DN. Although these associations do not reveal the 
function of miRNAs in human DN, examining associations between miRNAs and 
clinical manifestations can suggest candidate mechanisms. In addition, these data 
enable us to generate new hypotheses on specific miRNAs and potentially build 
models of mechanistic interactions. 
 
miR-21 and TGFβ-related glomerulopathy 
We discovered that miR-21 is protective in glomerulopathy. In TGFβ1 transgenic 
mice, miR-21 inhibits TGFβ-induced podocyte apoptosis and protects against 
glomerulosclerosis. miR-21 targets many tumor suppressor genes and has 
anti-apoptotic effect in cancer cells11,12. The innovation of the current finding lies on 
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the ability of miR-21 to inhibit podocyte apoptosis and the protective effect of 
miR-21 in glomerular injury. 
 
miR-21 elevates with renal damage in mice with different injury models and in 
patients with transplant nephropathy6,13,14. The increase of miR-21 promotes 
interstitial fibrosis after renal ischemia reperfusion and unilateral ureteral 
obstruction in mice6,13. However, the fibrogenic role of miR-21 remains 
controversial because results across different studies have not always been 
consistent15-17. For example, the inhibition of miR-21 in the heart disease induced by 
pressure overload attenuates interstitial fibrosis in mice, while the miR-21 null mice 
do not have the improved phenotype in the same disease model.  
 
In TGFβ1 transgenic mice, a model of progressive glomerulopathy, miR-21 
increased with the severity of the renal damage. Podocyte apoptosis induces 
glomerulopathy in TGFβ1 transgenic mice and miR-21 inhibits apoptosis of cancer 
cells. For that reason, we hypothesized that miR-21 can inhibit podocyte apoptosis 
to ameliorate glomerulopathy. 
 
Our experiments in mice confirmed the hypothesis that miR-21 is protective in 
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glomerulopathy, as TGFβ1 transgenic/miR-21 null mice displayed increased 
proteinuria, glomerulosclerosis, and ECM deposition in the glomeruli. The 
determination of podocyte number and the examination of podocyte apoptosis in 
TGFβ1 transgenic/miR-21 null mice confirmed that miR-21 protects against 
glomerulopathy through the inhibition of podocyte apoptosis. The anti-apoptotic 
effect of miR-21 was also shown in the cultured mouse podocytes. miR-21 
inhibition in mouse podocytes promoted cell apoptosis while miR-21 overexpression 
attenuated TGFβ-induced podocyte apoptosis. 
 
miR-21 targets multiple pro-apoptotic pathways, including Tgfbr2, Tgfbi, Smad7 
and Tp53. miR-21 also targets ECM-related factors, such as Timp3 and Col4a1. This 
is supported by our findings that the expression of those genes was increased in the 
glomeruli of TGFβ1 transgenic/miR-21 null mice. In addition, inhibition of miR-21 
in mouse podocytes increased the level of phosphorylation of Smad3, consistent 
with activation of TGFβ/Smad signaling. The inhibition of miR-21 in mouse 
podocytes also increased the protein level of PDCD4, a pro-apoptotic factor and a 
well-known target of miR-21.  
 
The luciferase assay confirmed that Smad7 is the sequence-dependent target of 
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miR-21. Other genes including Tgfbr2, Timp3, and Col4a1 have been reported as the 
direct target of miR-2118-20. Taken together, miR-21 targets multiple genes regulated 
by TGFβ, possibly as a feedback mechanism to limit TGFβ-induced podocyte 
apoptosis and ECM deposition in glomerulopathy.   
 
miR-21 and diabetic glomerulopathy 
The concept that miR-21 inhibits the devlopment of glomerulopathy is also 
supported by the fact that loss of miR-21 increased proteinuria and podocyte loss in 
STZ-treated miR-21 KO mice versus WT mice (Figure 5.1). In addition, we have 
detected increased mesangial expansion in STZ-treated miR-21 KO mice, which can 
be secondary to increased proliferation or activation of mesangial cells. 
  
To understand the mechanism of increased mesangial expansion in diabetic miR-21 
KO mice, we isolated primary mesangial cells (PMC) from miR-21 WT and KO 
mice. The scratch-wound assay, the MTT cell proliferation assay, and the 
examination of cell cycle distribution all indicated that loss of miR-21 promotes cell 
growth of PMC. Together with previous studies, our results strongly suggest that 
miR-21 regulates cell cycle in mesangial cells21,22. The further examination did 
reveal that the expression of Cdk6 and Cdc25a, which facilitates cell cycle 
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progression23,24, was increased in the glomeruli of STZ-treated miR-21 KO mice 
versus STZ-treated miR-21 WT mice. We further hypothesize that miR-21 limits 
mesangial cell proliferation by targeting Cdk6 and Cdc25a. 
 
The hypothesis requires further experimental validation. However, it can be 
speculated that the dominant effect of miR-21 in mesangial cells is to inhibit cell 
growth, whereas in podocytes is to inhibit apoptosis. This may also explain the 
discrepancy in the results that miR-21 is deleterious in tubulointerstitial injury yet 
miR-21 is protective in glomerular injury. These findings do not support that 
overexpression of miR-21 will ameliorate DN or other kidney diseases, unless 
cell-type specific increase of miR-21 can be achieved, but rather provide evidence 
that miR-21 and other miRNAs are multi-faceted. This adds complexity in future 
clinical application of miRNAs as targets to treat kidney diseases. 
 
Disease-associated miRNAs and disease-associated miRNAs 
In chapter 4, we investigated the associations of the expression of miRNA and 
mRNA with clinical manifestations of DN. We discovered that the expression of 
miRNAs and mRNAs in the glomeruli of patients with DN was correlated with urine 
albumin-to-creatinine ratio (ACR) of patients. Using results from PAR-CLIP 
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experiments and prediction algorithms based on sequence complementarity, we were 
able to identify a candidate target interaction between ACR-correlated miRNAs and 
ACR-correlated mRNAs. Accordingly, we found EXOC7 is the sequence-dependent 
target of miR-200a and RALGPS2 and SUPT6H are repressed by miR-200a in renal 
cells.  
 
Several different prediction algorithms to search for miRNA targets are available. 
However, experimental validation of those prediction algorithms is limited. Studies 
have proposed that differentially-expressed mRNAs are targets of inversely 
differentially-expressed miRNA in disease condition versus control25,26. Here, we 
presented a novel method revealing disease-associated mRNAs are targets of 
disease-associated miRNAs. Our rationale is that miRNAs, which are part of the 
disease mechanism, increase with disease progression in order to limit the 
upregulation of mRNAs associated with disease progression. This attempt of 
miRNAs aims at limiting the change of mRNAs, which are driven by the disease, 
thus no good inverse correlation was observed between the expression of miRNAs 
and the expression of their target mRNAs from the same study subjects. 
 
Our analysis showed that miR-200a was positively correlated with ACR. One gene, 
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RALGPS2, which was also positively correlated with ACR, was repressed by 
miR-200a in human embryonic kidney (HEK) cells. This finding supports the 
hypothesis that miRNAs increase with the disease progression in order to limit the 
upregulation of mRNAs associated with the disease progression. Interestingly, our 
experiments also revealed two genes, EXOC7 and SUPT6H, which were negatively 
correlated with ACR, were also repressed by miR-200a in HEK cells. According to 
this finding, we assume that miRNAs, increase with the disease progression, serve 
another purpose to aid the downregulation of mRNAs associated with the disease 
progression. 
 
Therefore, this approach represents an alternative method to facilitate the 
identification of miRNA targets. Our computational work also uncovered several 
ACR-correlated miRNAs. Additional research into the role of those miRNAs in DN 
is still needed. Although our research did not directly reveal the role of miR-200a 
and its targets in the progression of DN, it opens up possible new regulatory 
mechanisms of miR-200a in DN. Such a result strongly supports the future 






Cell-specific role of miR-21 
In the body of our work, we discovered that miR-21 inhibits podocyte apoptosis and 
limits mesangial expansion in glomerulopathy. This protective role of miR-21 is 
contrary to the finding that miR-21 promotes fibrogenesis in tubulointerstitial injury. 
This controversy adds to the complexity of therapeutic application aimed at using 
miR-21 inhibitor as a therapeutic drug in human kidney diseases. Additional 
research into the cell type-specific role and the mechanisms leading to this cell 
type-specific action of miR-21 is urgently needed. 
 
Although our initial result is intriguing, further studies need to be conducted to 
accurately define the cell type-specific role of miR-21. One standard approach to 
address this question is to challenge podocyte-specific or tubular cell-specific 
conditional miR-21 knockout (KO) mice with specific renal injury and examine the 
renal phenotype. The Podocin-Cre and Cdh16-Cre mice are mice expressing Cre 
recombinase specific to podocytes and renal tubule cells, respectively27,28. By 
crossing Podocin-Cre or Cdh16-Cre mice with miR-21 flox/flox mice29, we can 
evaluate the impact of loss of miR-21 on podocytes or tubule cells in specific renal 
injuries and explore the cell type-specific regulatory mechanisms of miR-21. If 
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miR-21 has a bi-faceted role of inhibiting podocyte apoptosis in renal glomeruli and 
promoting fibrotic change of tubular cells in tubulointerstitium6, we can interrogate 
the question whether the protective effect of miR-21 outweighs the deleterious effect 
of miR-21 in specific renal injuries. To answer this question, we now need to 
generate double podocyte-specific and tubular cell-specific conditional miR-21 KO 
mice. Challenging the double cell-specific miR-21 KO mice with glomerular and 
tubulointerstitial injury, we can more accurately evaluate the therapeutic effect of the 
inhibition of miR-21. Unfortunately, at present, mice expressing Cre recombinase 
specific to mesangial cells are not available.     
 
miR-21 as a biomarker in human kidney disease 
Our experiment showed that miR-21 increases with renal damage. This finding is 
consistent across different studies with different renal injuries and even in humans 
with different kidney diseases6,13,14. If the levels of miR-21 reflect the severity of 
renal damage, one can speculate that miR-21 serves as a biomarker of kidney 
damage and its higher level predicts the decline of renal function. This capacity of 
miR-21 would be independent of its function, but rather reflect its regulation by 




For long, the level of albuminuria has been used as the primary predictive marker 
for the progression of DN. However, recent studies have revealed the uncoupling 
between the progression of albuminuria and the declining of renal function30-32. The 
predictive accuracy of albuminuria by itself is still unsatisfactory. Despite many new 
biomarkers described, proper validation for the predictive ability of those new 
biomarkers is lacking33. To date, research into additional biomarkers is still needed. 
  
Urine collection is easily accessible and non-invasive. The analyses of urinary 
components other than albumin and the expression of genes, which are derived from 
urinary cells, have been described to monitor disease activity33-35. Lately, miRNAs 
have also been identified in urine supernatant containing microvesicles, which are 
the membrane-enclosed structure released by renal cells36,37. Because of these 
exciting results, we have established the method to measure the expression of 
miRNAs in urine supernatant. Using this assay, we are able to quantify the levels of 
miR-21 in the urine. The hypothesis is that miR-21, increased with renal damage, 
will be released by renal cells to urine supernatant either by microvesicles or in a 
circulating form. Future experiments will correlate the levels of urinary miR-21 with 
the expression of renal miR-21. If the levels of urinary miR-21 reflect the levels of 
miR-21 in the kidney, the next logical step is to correlate the levels of urinary 
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miR-21 with the severity of renal damage, such as kidney morphometry. Ultimately, 
we will examine the predictive ability of the levels of urinary miR-21 in the decline 
of renal function and in the development of end stage renal disease. 
 
Identify regulatory mechanism of miR-21 in diabetic mice 
Our findings suggest that miR-21 limits mesangial cell proliferation by targeting 
Cdk6 and Cdc25a,. To stringently test this hypothesis, confirmation of the protein 
level of Cdk6 and Cdc25a in renal glomeruli using immunohistochemical staining or 
western blot is required. In addition, in vitro experiments need to be conducted to 
support the findings in mice. We will examine the proliferation, cell cycle 
distribution, and the expression of Cdk6 and Cdc25a in PMC expressing antisense 
miR-21 oligonucleotides to test whether miR-21 targets Cdk6 and Cdc25a to inhibit 
mesangial cell growth.   
 
miR-200a and diabetic glomerulopathy 
In chapter 4, we have shown that miR-200a correlates with ACR of patients. We also 
developed a new computational method to identify potential targets of miRNAs. By 
this method, we discovered that miR-200a targets EXOC7 and miR-200a regulates 




At present, the role of miR-200a in diabetic glomerulopathy is still unclear. Kato et 
al. proposed that miR-200a, upregulated by TGFβ, targets Zeb1/Zeb2 to promote the 
expression of collagen1a2 in mesangial cells38. However, other studies showed that 
the downregulation of miR-200a by TGFβ increases the expression of Zeb1/Zeb2 to 
induce epithelial-to-mesenchymal transition (EMT) in cancer cells39,40. To address 
this issue, we need to first determine the level of the expression of miR-200a in the 
glomeruli of diabetic mice. To further determine the role of miR-200a in diabetic 
glomerulopathy, we will generate the miR-200a null diabetic mice or inject the 
diabetic mice with antisense miR-200a oligonucleotides. If there is a regulation or a 
role of miR-200a in diabetic glomerulopathy, the expression of Exoc7, Ralgps2, and 
Supt6h will also be determined in the glomeruli of the mice. From these data, 
additional hypotheses regarding the interrelation of miR-200a and its targets in 
diabetic glomerulopathy can be generated.  
 
Identity disease-associated miRNAs 
Our analyses identified several miRNAs exhibit significant correlation with ACR. 
The functions of some of those miRNAs have been explored in cancer model 
systems, including miR-135a promoting growth and migration of cancer cells41,42, 
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miR-218 limiting the invasiveness of cancer cells43, and miR-142-3p regulating 
differentiation of myeloid cells44. For each miRNA, new hypotheses can be 
generated and validated in animal models of DN.  
 
The data of kidney morphometry of the kidney biopsies of patients with DN, which 
were used for profiling the expression of miRNAs and mRNAs, are available. 
Examining associations of miRNAs and mRNAs with kidney morphometry can 
identify miRNAs and mRNAs correlating with specific parameters. Using the 
newly-proposed method in chapter 4 for discovering targets of miRNAs, we are able 
to generate additional hypotheses about the modulations among miRNAs, mRNAs, 
and DN. Besides validating the hypotheses experimentally in tissue culture as well 
as in mouse models, we will further use Ingenuity Pathway Analysis45 to construct 
dynamic pathway networks among kidney morphometry-associated miRNAs and 
mRNAs. This approach will generate a broader view of how miRNAs modulate DN 












Figure 5.1. Examination of podocyte number in glomeruli of STZ-treated 
miR-21 WT and KO mice. At 20 weeks after STZ treatment, podocyte number 
significantly decreased in STZ-treated miR-21-KO mice versus WT mice (N=5) (*P 
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